Original Article
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
N Engl J Med 2009; 360:354-362January 22, 2009
- Abstract
Background
Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function.
Methods
We tested the association between functional genetic variants in CYP genes, plasma concentrations of active drug metabolite, and platelet inhibition in response to clopidogrel in 162 healthy subjects. We then examined the association between these genetic variants and cardiovascular outcomes in a separate cohort of 1477 subjects with acute coronary syndromes who were treated with clopidogrel in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON–TIMI) 38.
Results
In healthy subjects who were treated with clopidogrel, carriers of at least one CYP2C19 reduced-function allele (approximately 30% of the study population) had a relative reduction of 32.4% in plasma exposure to the active metabolite of clopidogrel, as compared with noncarriers (P<0.001). Carriers also had an absolute reduction in maximal platelet aggregation in response to clopidogrel that was 9 percentage points less than that seen in noncarriers (P<0.001). Among clopidogrel-treated subjects in TRITON–TIMI 38, carriers had a relative increase of 53% in the composite primary efficacy outcome of the risk of death from cardiovascular causes, myocardial infarction, or stroke, as compared with noncarriers (12.1% vs. 8.0%; hazard ratio for carriers, 1.53; 95% confidence interval [CI], 1.07 to 2.19; P=0.01) and an increase by a factor of 3 in the risk of stent thrombosis (2.6% vs. 0.8%; hazard ratio, 3.09; 95% CI, 1.19 to 8.00; P=0.02).
Conclusions
Among persons treated with clopidogrel, carriers of a reduced-function CYP2C19 allele had significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of major adverse cardiovascular events, including stent thrombosis, than did noncarriers.
Media in This Article
Figure 1
Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel.Figure 2
Relationship between CYP2C19 Genetic Classification and Pharmacokinetic and Pharmacodynamic Responses after the Administration of Loading and Maintenance Doses of Clopidogrel in Healthy Subjects.Article Activity
- Article
Across the spectrum of acute coronary syndromes and in patients undergoing percutaneous coronary interventions (PCI) with stenting, dual antiplatelet therapy with aspirin and clopidogrel, a thienopyridine inhibitor of the platelet P2Y12 adenosine diphosphate (ADP) receptor, is the standard of care.1-3 However, the pharmacodynamic response to clopidogrel has substantial interpatient variability,4-6 and patients with coronary disease with lesser degrees of platelet inhibition in response to clopidogrel appear to be at increased risk for cardiovascular events.7-10
Clopidogrel is a prodrug that requires biotransformation to an active metabolite by cytochrome P-450 (CYP) enzymes (Figure 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).11,12 Moreover, esterases shunt the majority of clopidogrel to an inactive pathway, with the remaining prodrug requiring two separate CYP-dependent oxidative steps. The genes encoding the CYP enzymes are polymorphic, and extensive data have shown that certain alleles confer reduced enzymatic function.13 Data regarding in vitro metabolism and clinical outcomes suggest that the reduced-function CYP polymorphisms have an effect on the conversion to active metabolite and hence on the degree of platelet inhibition associated with clopidogrel.14-16
We therefore hypothesized that patients carrying a genetic variant that diminished the pharmacokinetic and pharmacodynamic response to clopidogrel would have a higher rate of ischemic events than patients who were noncarriers. To test this hypothesis, we first examined the association between functional polymorphisms in CYP genes with plasma exposure to the active metabolite of clopidogrel and platelet inhibition in healthy subjects. We then determined whether reduced-function CYP alleles were associated with a higher rate of adverse cardiovascular outcomes in a separate cohort of subjects with acute coronary syndromes who were treated with clopidogrel in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON–TIMI) 38 (ClinicalTrials.gov number, NCT00097591).
Methods
Pharmacokinetic and Pharmacodynamic Response in Healthy Subjects
We included 162 healthy subjects from six studies involving thienopyridine treatment in the pharmacokinetic and pharmacodynamic analyses (Table 1 in the Supplementary Appendix).17-22 Plasma concentrations of the active metabolite of clopidogrel were measured by liquid chromatography with mass spectrometry.23 The area under the plasma concentration–time curve from the time of administration to the last measurable concentration (AUC0−t) of active metabolite was computed by noncompartmental methods of analysis with the use of the log-linear trapezoidal method. The pharmacodynamic response, which was assessed with the use of light transmission aggregometry in response to 20 μM of ADP, was expressed as an absolute reduction in maximal platelet aggregation from baseline (ΔMPA).
Clinical Outcomes
The design and primary results of TRITON–TIMI 38 have been described previously.24,25 Patients with acute coronary syndromes with planned PCI who were randomly assigned to treatment with clopidogrel received a 300-mg loading dose, followed by a 75-mg daily maintenance dose for up to 15 months. The primary efficacy outcome was a composite of death from cardiovascular causes, myocardial infarction, or stroke. A key prespecified secondary outcome was definite or probable stent thrombosis, as defined by the Academic Research Consortium.26 Safety outcomes included TIMI major or minor bleeding not related to coronary-artery bypass grafting (CABG). All outcomes were adjudicated by a clinical events committee whose members were unaware of study-group assignments. The clopidogrel pharmacogenetic analysis included 1477 subjects who provided a DNA sample (Table 2 in the Supplementary Appendix).
All studies were approved by the institutional review board at each center, and written informed consent was obtained from all subjects. In keeping with the informed-consent and privacy policies, all genetic data resided with the sponsor (Eli Lilly) in a deidentified database behind a firewall and were analyzed by statisticians distinct from those who had access to the clinical database. The genetic studies were designed and performed in collaboration between the TIMI Study Group and the sponsors, Eli Lilly and Daiichi Sankyo. The academic authors directed and had access to all the analyses and the full clinical database, wrote all drafts of the manuscript, decided to publish the results, and vouch for the accuracy and completeness of the data.
Genotyping Methods
A total of 98% of the genotyping procedures were performed with the use of the Affymetrix Targeted Human DMET (drug-metabolizing enzymes and transporters) 1.0 Assay (Affymetrix).27,28 In the case of CYP2C19*17 or a no-call on the DMET chip (2% of samples), genotyping was performed with bidirectional sequencing or exon-specific polymerase-chain-reaction amplification, followed by the use of standard agarose-gel electrophoresis to resolve restriction-fragment–length polymorphisms. A total of 54 alleles, comprising the known major functional variants, were determined with the use of clinically validated assays for CYP2C19, CYP2C9, CYP2B6, CYP3A5, CYP3A4, and CYP1A2 (Table 3 in the Supplementary Appendix). Of note, the tested alleles in CYP3A4 were not polymorphic, which left five genes for analysis. Genotypes were presumed to be in Hardy–Weinberg equilibrium if the P value was more than 0.001 (0.05/50 alleles=0.001).
CYP Genotype Classifications
Each allele of the CYP genes was classified a priori by its known effect on enzymatic function according to the literature and with the use of established common-consensus star allele nomenclature.13,29,30 For each CYP gene, subjects were dichotomized a priori into two groups on the basis of whether they possessed at least one allele with significantly reduced function. If we observed a significant pharmacokinetic or pharmacodynamic effect, further analysis was undertaken with the use of an a priori extended categorical classification, which included ultrarapid, extensive, intermediate, and poor metabolizer genotypes. In the Supplementary Appendix, Table 4 lists the observed genotypes and their classification, and Table 5 provides the baseline characteristics in carriers and noncarriers of a reduced-function CYP2C19 allele among subjects receiving clopidogrel in TRITON–TIMI 38.
Statistical Analysis
Pharmacokinetic and Pharmacodynamic Responses
The associations between genetic variation and pharmacokinetic and pharmacodynamic measures were tested with the use of likelihood-ratio tests based on linear mixed-effects models, with the primary outcomes being exposure to the active metabolite of clopidogrel (log[AUC0−t]) and platelet inhibition (reduction in maximal platelet aggregation [ΔMPA]) in response to clopidogrel. The models contained the subject as a random effect, status as a reduced-function allele carrier as the predictor of main interest, and other fixed effects, including study, dose, and ethnic background; for the pharmacodynamic response, also included were the time of administration, the interaction between the dose and time, and the baseline MPA. To account for other potential baseline differences, additional demographic variables (age, sex, weight, and smoking status) were included, as determined by forward selection for each model. Two-sided P values were calculated, and a significance threshold of P<0.01 was used to correct for multiple hypotheses testing for the five CYP genes.
Clinical Outcomes
Rates of the outcomes were expressed as Kaplan–Meier estimates at 15 months and were compared between carriers and noncarriers of at least one reduced-function CYP allele. Consistent with the primary trial analyses, the Gehan–Wilcoxon test was used for the primary efficacy outcome and the log-rank test for other outcomes.24 Hazard ratios and 95% confidence intervals were calculated on the basis of Cox proportional-hazards regression models with clinical syndrome (acute coronary syndromes with or without ST elevation) as a stratification factor. Using the findings in healthy subjects, we tested the association between carriage of a reduced-function variant in CYP2C19 and a higher rate of adverse clinical outcomes in subjects assigned to treatment with clopidogrel as the primary hypothesis for analysis in TRITON–TIMI 38. A two-sided P value was used to test for significance (threshold, P<0.05). If a significant relationship between genotype classification and the primary efficacy outcome was identified, we then explored additional efficacy outcomes, including components of the composite primary efficacy outcome and stent thrombosis. Sensitivity analyses comparing CYP2C19*2 carriers with noncarriers were performed in a similar manner. Other genes were investigated in an exploratory manner.
Results
Pharmacokinetic and Pharmacodynamic Responses
For the pharmacokinetic and pharmacodynamic analyses, DNA samples were available for 162 healthy subjects who were treated with clopidogrel. The mean (±SD) age was 34.4±12.8 years, and 20% were women. After 4 hours, treatment with a 300-mg dose of clopidogrel resulted in a mean absolute reduction in platelet aggregation (ΔMPA) of 36.0±20.5 percentage points.
The associations between the presence of a reduced-function CYP allele and both plasma exposure to the active metabolite of clopidogrel and platelet inhibition are presented in Figure 1Figure 1
Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel.. Carriers of at least one CYP2C19 reduced-function allele (34% of the study population) had a relative reduction of 32.4% in plasma exposure to the active metabolite, as compared with noncarriers (P<0.001). Carriers also had a diminished pharmacodynamic response, with an absolute ΔMPA in response to clopidogrel that was 9 percentage points less than that seen in noncarriers (P<0.001), or a relative reduction of approximately 25%.The pharmacokinetic and pharmacodynamic effects of a CYP2C19 reduced-function allele on the response to clopidogrel were observed after a loading dose (either 300 mg or 600 mg) and during the administration of a maintenance dose (Table 6 in the Supplementary Appendix). Furthermore, when the extended CYP2C19 genotypic classification was used (ultrarapid, extensive, intermediate, and poor metabolizer genotypes), there was a gradient of effect: subjects with the ultrarapid-metabolizer genotypes had the highest exposure to active metabolite and the greatest platelet inhibition, and subjects with the poor-metabolizer genotypes had the lowest exposure and least platelet inhibition with both loading and maintenance doses (Figure 2Figure 2
Relationship between CYP2C19 Genetic Classification and Pharmacokinetic and Pharmacodynamic Responses after the Administration of Loading and Maintenance Doses of Clopidogrel in Healthy Subjects.).As compared with noncarriers, carriers of a reduced-function CYP2B6 allele tended to have lower plasma exposure to the active metabolite of clopidogrel (a relative reduction of 15.7%) and tended to have less reduction of platelet aggregation in response to clopidogrel (an absolute difference in ΔMPA of 5.7 percentage points). Carrier status for a reduced-function allele for the other three CYP genes (CYP2C9, CYP3A5, and CYP1A2) was not associated with a consistent attenuation of the pharmacokinetic and pharmacodynamic responses to clopidogrel.
Clinical Outcomes
DNA samples were available for 1477 subjects who were assigned to treatment with clopidogrel in TRITON–TIMI 38. Their mean age was 60.1±11.1 years, 29.3% were women, 71.0% presented with non–ST-elevation acute coronary syndromes, and 29.0% presented with ST-elevation myocardial infarction.
Concordant with and extending the pharmacokinetic and pharmacodynamic findings, 395 subjects carrying at least one CYP2C19 reduced-function allele (27.1% of the study population) were at significantly higher risk for the primary efficacy outcome of death from cardiovascular causes, myocardial infarction, or stroke than were noncarriers (12.1% vs. 8.0%; hazard ratio for carriers, 1.53; 95% confidence interval [CI], 1.07 to 2.19; P=0.01) (Figure 3AFigure 3
Association between Status as a Carrier of a CYP2C19 Reduced-Function Allele and the Primary Efficacy Outcome or Stent Thrombosis in Subjects Receiving Clopidogrel.).A directionally consistent hazard was observed among subjects carrying a CYP2C19 reduced-function allele for each of the components of the primary efficacy outcome, as compared with noncarriers, including death from cardiovascular causes (2.0% vs. 0.4%; hazard ratio, 4.79; 95% CI, 1.40 to 16.37), nonfatal myocardial infarction (10.1% vs. 7.5%; hazard ratio, 1.38; 95% CI, 0.94 to 2.02), and nonfatal stroke (0.88% vs. 0.24%; hazard ratio, 3.93; 95% CI, 0.66 to 23.51). The risk of stent thrombosis in carriers of a CYP2C19 reduced-function allele was three times that among noncarriers (2.6% vs. 0.8%; hazard ratio, 3.09; 95% CI, 1.19 to 8.00; P=0.02) (Figure 3B).
For CYP2C19, the presence of at least one copy of the *2 allele accounted for 95% of the subjects who were classified as carriers of a reduced-function allele. CYP2C19*2 carriers had a higher rate of the primary efficacy outcome (11.7% vs. 8.3%; hazard ratio, 1.42; 95% CI, 0.98 to 2.05; P=0.04) and of stent thrombosis (2.7% vs. 0.8%; hazard ratio, 3.33; 95% CI, 1.28 to 8.62; P=0.004) than did noncarriers.
No significant associations between any of the other CYP genotypes and the primary efficacy outcome were observed, nor did the rates of non–CABG-related TIMI major or minor bleeding differ significantly across any CYP genotype (Table 1Table 1
Efficacy and Safety Outcomes at 15 Months in Subjects Treated with Clopidogrel, According to Genotype Status.).Discussion
Our results provide strong evidence linking CYP genetic variation to a reduced exposure to the active drug metabolite, less platelet inhibition, and less protection from recurrent ischemic events in persons receiving clopidogrel. Specifically, common polymorphisms in the CYP2C19 gene, seen in approximately 30% of whites, 40% of blacks, and more than 55% of East Asians,31 significantly diminish both the pharmacokinetic and pharmacodynamic responses to clopidogrel by approximately one quarter to one third. In addition, our findings show that in patients with acute coronary syndromes treated with clopidogrel, the same variants in CYP2C19 were associated with adverse clinical outcomes, including a rate of death from cardiovascular causes, myocardial infarction, or stroke that was more than 50% greater and a rate of stent thrombosis that was greater by a factor of three than the rate in noncarriers.
There are compelling biologic data to support these findings. CYP2C19 contributes in both of the two sequential oxidative metabolic steps of clopidogrel activation. Slowing the first step would tend to shunt the prodrug preferentially to an esterase-mediated pathway forming pharmacologically inactive metabolites (Figure 1 in the Supplementary Appendix). CYP2C19*2 was the most frequent variant allele (95%) among the reduced-function group. This loss-of-function variant encodes a cryptic splice variant that leads to no enzymatic activity.32 Data from several studies support the observations regarding reduced-function CYP2C19 polymorphisms and platelet aggregation among clopidogrel-treated subjects.10,15,33 However, these studies examined fewer polymorphisms than we did and did not have sufficient power to demonstrate an association between genotype and clinical outcome. Our study involved more extensive genotyping of the CYP genes relevant to clopidogrel metabolism and evaluated the association with exposure to the active metabolite of clopidogrel, platelet inhibition, and cardiovascular outcomes. These findings enabled us to assess the consistency in biologic effects of genetic variants across these measures.
There are several potential limitations to our study. First, although we genotyped multiple known functional variants in the relevant CYP genes in a large cohort, some rare functional variants were not observed in our population. We cannot exclude meaningful effects of these and other genetic variants that either were not identified or had incomplete functional characterization.34,35 Moreover, since variations in non-CYP genes may also have an effect on responsiveness to clopidogrel and the likelihood of ischemic events, such variations also merit study. Likewise, there were so few homozygotes for any allele that we could not perform meaningful analyses regarding clinical events. Second, owing to the complexity of the sample handling and assays necessary for the pharmacokinetic and pharmacodynamic assessments, these evaluations could not be widely implemented in TRITON–TIMI 38, a large, multinational clinical trial. Thus, our platelet-aggregation studies were done in healthy subjects, not in patients with coronary disease. In addition, multiple genetic and environmental factors may contribute to platelet aggregation. However, by examining the change in platelet aggregation after the administration of clopidogrel, we attempted to control for factors that might have an effect on baseline platelet reactivity. Third, among subjects receiving clopidogrel, we might have expected to observe a lower rate of bleeding among carriers of a CYP2C19 reduced-function allele than among noncarriers. However, given the low rate of bleeding events, the power to detect significant differences in bleeding on the basis of genotype was limited in TRITON–TIMI 38.
In conclusion, we have shown that genetic variation has an effect on pharmacologic and clinical responses to clopidogrel. Carriers of a reduced-function CYP2C19 allele have significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of major adverse cardiovascular events, including stent thrombosis.
Supported by research grants from Daiichi Sankyo and Eli Lilly.
The TIMI Study Group reports receiving grant support from Daiichi Sankyo, Eli Lilly, Sanofi-Aventis, and Schering-Plough. In addition, Dr. Mega reports receiving grant support from Schering-Plough; Dr. Wiviott, grant support from Daiichi Sankyo, Eli Lilly, and Sanofi-Aventis, consulting fees from AstraZeneca and Sanofi-Aventis, and lecture fees from Daiichi-Sankyo, Eli Lilly, and AstraZeneca; Dr. Antman, grant support from Daiichi Sankyo and Eli Lilly, consulting fees from Sanofi-Aventis, and lecture fees from Eli Lilly and Sanofi-Aventis; Dr. Braunwald, grant support from Daiichi Sankyo, Eli Lilly, Sanofi-Aventis, and Schering-Plough, consulting fees from Daiichi Sankyo, Eli Lilly, and Schering-Plough, and lecture fees from Eli Lilly and Schering-Plough; and Dr. Sabatine, grant support from Sanofi-Aventis and Schering-Plough, consulting fees from AstraZeneca, Bristol-Myers Squibb, and Sanofi-Aventis, and lecture fees from Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, and Sanofi-Aventis. Dr. Walker reports being an employee of Daiichi Sankyo and having an equity interest or stock options in the company; and Drs. Close, Shen, Hockett, Brandt, and Macias, being employees of Eli Lilly and having an equity interest or stock options in the company.
No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0809171) was published at NEJM.org on December 22, 2008.
Source Information
From the Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (J.L.M., S.D.W., E.M.A., E.B., M.S.S.); Eli Lilly Research Laboratories, Indianapolis (S.L.C., L.S., R.D.H., J.T.B., W.M.); and Daiichi Sankyo Pharma Development, Edison, NJ (J.R.W.).
Address reprint requests to Dr. Mega or Dr. Sabatine at the Cardiovascular Division, Brigham and Women's Hospital, 350 Longwood Ave., Boston, MA 02115, or at jmega@partners.org or msabatine@partners.org.
- References
References
1
The Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trial Investigators
Full Text | Web of Science | Medline2
Sabatine MS ,Cannon CP ,Gibson CM , et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-1189
Full Text | Web of Science | Medline3
King SB III ,Smith SC Jr ,Hirshfeld JW Jr , et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Circulation 2008;117:261-295[Erratum, Circulation 2008;117(6):e161.]
CrossRef | Web of Science | Medline4
Gurbel PA ,Bliden KP ,Hiatt BL ,O'Connor CM . Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913
CrossRef | Web of Science | Medline5
O'Donoghue M ,Wiviott SD . Clopidogrel response variability and future therapies: clopidogrel: does one size fit all? Circulation 2006;114:e600-e606
CrossRef | Web of Science | Medline6
Angiolillo DJ ,Fernandez-Ortiz A ,Bernardo E , et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-1516
CrossRef | Web of Science | Medline7
Matetzky S ,Shenkman B ,Guetta V , et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175
CrossRef | Web of Science | Medline8
Hochholzer W ,Trenk D ,Bestehorn HP , et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-1750
CrossRef | Web of Science | Medline9
Gurbel PA ,Bliden KP ,Samara W , et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005;46:1827-1832
CrossRef | Web of Science | Medline10
Trenk D ,Hochholzer W ,Fromm MF , et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51:1925-1934
CrossRef | Web of Science | Medline11
Kurihara A ,Hagihara K ,Kazui M ,Ishizuka T ,Farid NA ,Ikeda T . In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation. Drug Metab Rev 2005;37:Suppl 2:99-9912
Rehmel JL ,Eckstein JA ,Farid NA , et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006;34:600-607
CrossRef | Web of Science | Medline13
Ingelman-Sundberg M ,Sim SC ,Gomez A ,Rodriguez-Antona C . Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496-526
CrossRef | Web of Science | Medline14
Farid NA ,Payne CD ,Small DS , et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-741
CrossRef | Web of Science | Medline15
Brandt JT ,Close SL ,Iturria SJ , et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-2436
CrossRef | Web of Science | Medline16
Kim KA ,Park PW ,Hong SJ ,Park JY . The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008;84:236-242
CrossRef | Web of Science | Medline17
Payne CD ,Li YG ,Small DS , et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007;50:555-562
CrossRef | Web of Science | Medline18
Small DS ,Payne CD ,Kothare PA , et al. Comparison of pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel loading doses in healthy Chinese and Caucasian subjects. Clin Pharmacol Ther 2008;83:Suppl 1:S56-S56
Web of Science19
Payne CD ,Li YG ,Brandt JT , et al. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets 2008;19:275-281
CrossRef | Web of Science | Medline20
Small DS ,Farid NA ,Li YG , et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin 2008;24:2251-2257
CrossRef | Web of Science | Medline21
Farid NA ,Small DS ,Payne CD , et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy 2008;28:1483-1494
CrossRef | Web of Science | Medline22
Li YG ,Ni L ,Small D , et al. Inhibition of platelet aggregation with prasugrel and clopidogrel. Am J Cardiol 2008;102:Suppl:76i-76i
CrossRef | Web of Science23
Farid NA ,McIntosh M ,Garofolo F , et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21:169-179
CrossRef | Web of Science | Medline24
Wiviott SD ,Antman EM ,Gibson CM , et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006;152:627-635
CrossRef | Web of Science | Medline25
Wiviott SD ,Braunwald E ,McCabe CH , et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015
Full Text | Web of Science | Medline26
Wiviott SD ,Braunwald E ,McCabe CH , et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008;371:1353-1363
CrossRef | Web of Science | Medline27
Daly TM ,Dumaual CM ,Miao X , et al. Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. Clin Chem 2007;53:1222-1230
CrossRef | Web of Science | Medline28
Dumaual C ,Miao X ,Daly TM , et al. Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. Pharmacogenomics 2007;8:293-305
CrossRef | Web of Science | Medline29
Special report: genotyping for cytochrome P450 polymorphisms to determine drug-metabolizer status: TEC assessment. Chicago: Blue Cross Blue Shield Technology Evaluation Center Assessment Program, 2004.
30
Karolinska Institute. Human Cytochrome P450 (CYP) Allele Nomenclature Committee home page. (Accessed December 29, 2008, at http://www.cypalleles.ki.se.)
31
Desta Z ,Zhao X ,Shin JG ,Flockhart DA . Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-958
CrossRef | Web of Science | Medline32
de Morais SM ,Wilkinson GR ,Blaisdell J ,Nakamura K ,Meyer UA ,Goldstein JA . The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-15422
Web of Science | Medline33
Hulot JS ,Bura A ,Villard E , et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108:2244-2247
CrossRef | Web of Science | Medline34
Angiolillo DJ ,Fernandez-Ortiz A ,Bernardo E , et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006;26:1895-1900
CrossRef | Web of Science | Medline35
Suh JW ,Koo BK ,Zhang SY , et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006;174:1715-1722[Erratum, CMAJ 2006;175:64.]
CrossRef | Web of Science | Medline
- Citing Articles (496)
Citing Articles
1
Masato Ohbuchi, Kiyoshi Noguchi, Akio Kawamura, Takashi Usui. (2012) Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica1-8
CrossRef2
Lisa K. Jennings, Alan D. Michelson, Mary V. Jacoski, Aditya Tyagi, Svetozar Grgurevich, Jennifer S. Li, for the PICOLO Investigators. (2012) Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: A comparative study of platelet aggregation response. Platelets1-9
CrossRef3
Luke Kim, Konstantinos Charitakis, Rajesh V. Swaminathan, Dmitriy N. Feldman. (2012) Novel Antiplatelet Therapies. Current Atherosclerosis Reports 14:1, 78-84
CrossRef4
Robert W. Harrison, Kenneth W. Mahaffey. (2012) Clopidogrel and PPI Interaction: Clinically Relevant or Not?. Current Cardiology Reports 14:1, 49-58
CrossRef5
Joan Chen, Yuhong Cathy Yuan, Grigorios I. Leontiadis, Colin W. Howden. (2012) Recent Safety Concerns With Proton Pump Inhibitors. Journal of Clinical Gastroenterology 46:2, 93-114
CrossRef6
Erin Y Oh, Teena Abraham, Nasser Saad, Jonathan H Rapp, Fabienne L Vastey, Eric Balmir. (2012) A comprehensive comparative review of adenosine diphosphate receptor antagonists. Expert Opinion on Pharmacotherapy 13:2, 175-191
CrossRef7
Francis K L Chan. (2012) Anti-platelet therapy and managing ulcer risk. Journal of Gastroenterology and Hepatology 27:2, 195-199
CrossRef8
Gabriele Pesarini, Francesco Santini, Giulia Geremia, Carlo Zivelonghi, Flavio Ribichini. (2012) Risk Stratification in Acute Coronary Syndromes. Journal of Cardiovascular Translational Research 5:1, 1-10
CrossRef9
Stuart A. Scott, Katrin Sangkuhl, Alan R. Shuldiner, Jean-Sébastien Hulot, Caroline F. Thorn, Russ B. Altman, Teri E. Klein. (2012) PharmGKB summary. Pharmacogenetics and Genomics 22:2, 159-165
CrossRef10
J T Delaney, A H Ramirez, E Bowton, J M Pulley, M A Basford, J S Schildcrout, Y Shi, R Zink, M Oetjens, H Xu, J H Cleator, E Jahangir, M D Ritchie, D R Masys, D M Roden, D C Crawford, J C Denny. (2012) Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record. Clinical Pharmacology & Therapeutics 91:2, 257-263
CrossRef11
Julio F. Marchini, Andre Manica, Kevin Croce. (2012) Stent Thrombosis: Understanding and Managing a Critical Problem. Current Treatment Options in Cardiovascular Medicine 14:1, 91-107
CrossRef12
Thomas Höchtl, Iannis Tentzeris, Karsten Schrör, Kurt Huber. (2012) Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents. Fundamental & Clinical Pharmacology 26:1, 2-10
CrossRef13
Sandra L. Close. (2012) Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant?. Fundamental & Clinical Pharmacology 26:1, 19-26
CrossRef14
Harvey D. White, Derek P. Chew, Harold L. Dauerman, Kenneth W. Mahaffey, C. Michael Gibson, Gregg W. Stone, Luis Gruberg, Robert A. Harrington, Deepak L. Bhatt. (2012) Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. American Heart Journal 163:2, 182-190.e4
CrossRef15
Joseph McGraw, Donald Waller. (2012) Cytochrome P450 variations in different ethnic populations. Expert Opinion on Drug Metabolism & Toxicology1-12
CrossRef16
Anahita Bhathena, David A. Katz. 2012. Genetics of Drug Disposition. .
CrossRef17
Thomas Gremmel, Karin Frühwirth, Christoph W. Kopp, Alexandra Kaider, Sabine Steiner, Tamam Bakchoul, Ulrich J. H. Sachs, Renate Koppensteiner, Simon Panzer. (2012) Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity. Clinical Research in Cardiology
CrossRef18
Nabel, Elizabeth G., Braunwald, Eugene, . (2012) A Tale of Coronary Artery Disease and Myocardial Infarction. New England Journal of Medicine 366:1, 54-63
Full Text19
J. J. W. Verschuren, S. Trompet, J. A. M. Wessels, H.-J. Guchelaar, M. P. M. de Maat, M. L. Simoons, J. W. Jukema. (2012) A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?. European Heart Journal 33:2, 165-175
CrossRef20
Alberto Menozzi, Daniela Lina, Giulio Conte, Francesco Mantovani, Diego Ardissino. (2012) Antiplatelet therapy in acute coronary syndromes. Expert Opinion on Pharmacotherapy 13:1, 27-42
CrossRef21
Ronan P. Kelly, Sandra L. Close, Nagy A. Farid, Kenneth J. Winters, Lei Shen, Fanni Natanegara, Joseph A. Jakubowski, Mary Ho, Joseph R. Walker, David S. Small. (2012) Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. British Journal of Clinical Pharmacology 73:1, 93-105
CrossRef22
Mao Chen, Xiao-Jing Liu, Shao-Di Yan, Yong Peng, Hua Chai, Qiao Li, Jia-Fu Wei, Yuan-Ning Xu, De-Jia Huang. (2012) Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease. Atherosclerosis 220:1, 168-171
CrossRef23
Lara Magro, Ugo Moretti, Roberto Leone. (2012) Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions. Expert Opinion on Drug Safety 11:1, 83-94
CrossRef24
Charles M. Strom, Dana Goos, Beryl Crossley, Ke Zhang, Arlene Buller-Burkle, Michael Jarvis, Franklin Quan, Mei Peng, Weimin Sun. (2012) Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory. Genetics in Medicine 14:1, 95-100
CrossRef25
Xiao-dong Wang, Dai-fu Zhang, Xue-bo Liu, Yan Lai, Wei-gang Qi, Yu Luo, Bo Hu, Yi-an Yao. (2012) Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance. European Journal of Internal Medicine 23:1, 48-53
CrossRef26
H. J. Bouman, J. W. van Werkum, G. Rudež, C. M. Hackeng, F. W. G. Leebeek, H. ten Cate, J. M. ten Berg, M. P. M. de Maat. (2012) The relevance of P2Y12-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: A clinical follow-up. Thrombosis and Haemostasis 107:1, 189-191
CrossRef27
Mizuhiro Arima, Atsushi Matsuda, Manabu Nitta, Keiko Yoshida, Makoto Shimizu. (2012) A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent. Heart and Vessels 27:1, 106-109
CrossRef28
Ken Kozuma. (2012) Proton-Pump Inhibitors. Circulation Journal 76:1, 41-42
CrossRef29
L. M. Rademakers, W. Dewilde, D. Kerkhof. (2012) Early double stent thrombosis associated with clopidogrel hyporesponsivenesss. Netherlands Heart Journal 20:1, 38-41
CrossRef30
Cody J. Peer, Shawn D. Spencer, Dustin A.H. VanDenBerg, Michael A. Pacanowski, Richard B. Horenstein, William D. Figg. (2012) A sensitive and rapid ultra HPLC–MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. Journal of Chromatography B 880, 132-139
CrossRef31
John A. Springer, Nicholas V. Iannotti, Jon E. Sprague, Michael D. Kane. (2012) Construction of a Drug Safety Assurance Information System Based on Clinical Genotyping. ISRN Bioinformatics 2012, 1-9
CrossRef32
Kyung Woo Park, Hyo-Soo Kim. (2012) Options to Overcome Clopidogrel Response Variability. Circulation Journal 76:2, 287-292
CrossRef33
Laurent Bonello, Laurence Camoin-Jau, Julien Mancini, Jacques Bessereau, Charlotte Grosdidier, Marie-Christine Alessi, Michel Ostorero, Françoise Dignat-George, Franck Paganelli. (2012) Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. Thrombosis Research
CrossRef34
Mladen Tzvetkov, Nicolas von Ahsen. (2012) Pharmacogenetic screening for drug therapy. Pathology1
CrossRef35
Soha Namazi, Javad Kojuri, Andia Khalili, Negar Azarpira. (2012) The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. Biochemical Pharmacology
CrossRef36
Sweta Goswami, Angela Cheng-Lai, James Nawarskas. (2012) Clopidogrel and Genetic Testing. Cardiology in Review1
CrossRef37
Ankie M. Harmsze, Jochem W. van Werkum, Christian M. Hackeng, Hendrik J.T. Ruven, Johannes C. Kelder, Heleen J. Bouman, Nicoline J. Breet, Jurriën M. ten Berg, Olaf H. Klungel, Anthonius de Boer, Vera H.M. Deneer. (2012) The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenetics and Genomics1
CrossRef38
Thomas Cuisset, Pierre-Emmanuel Morange, Marie-Christine Alessi. (2011) Recent advances in the pharmacogenetics of clopidogrel. Human Genetics
CrossRef39
Lauren B. Gerson, Donal McMahon, Ingram Olkin, Christopher Stave, Stanley G. Rockson. (2011) Lack of Significant Interactions Between Clopidogrel and Proton Pump Inhibitor Therapy: Meta-Analysis of Existing Literature. Digestive Diseases and Sciences
CrossRef40
Peter Damman, Pier Woudstra, Wichert J. Kuijt, Robbert J. Winter, Stefan K. James. (2011) P2Y12 platelet inhibition in clinical practice. Journal of Thrombosis and Thrombolysis
CrossRef41
(2011) How much of the world do you need for meaningful clinical trials? * Christmas Greetings 2011 * Book review: 'Cardiovascular catheterization and intervention' * A Textbook of Coronary, Peripheral, and Structural Heart Disease * The Brazilian Archives of Cardiology is the only cardiology journal in Latino America and the Southern hemisphere with an impact factor * The Mediterranean Diet, Part II * The TIMI story. European Heart Journal 32:24, 3057-3063
CrossRef42
Takamichi Ono, Koichi Kaikita, Seiji Hokimoto, Satomi Iwashita, Koichiro Yamamoto, Yuji Miyazaki, Eiji Horio, Koji Sato, Kenichi Tsujita, Tomohide Abe, Mariko Deguchi, Shinji Tayama, Hitoshi Sumida, Seigo Sugiyama, Hiroshige Yamabe, Sunao Nakamura, Kazuko Nakagawa, Hisao Ogawa. (2011) Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Thrombosis Research 128:6, e130-e136
CrossRef43
J A Talameh, H L McLeod. (2011) PON1 Q192R and Clopidogrel: A Case of the Winner’s Curse or Inadequate Replication?. Clinical Pharmacology & Therapeutics 90:6, 771-774
CrossRef44
Yan Ping Liu, Pan Pan Hao, Ming Xiang Zhang, Cheng Zhang, Fei Gao, Yun Zhang, Yu Guo Chen. (2011) Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: An updated meta-analysis. Thrombosis Research 128:6, 593-594
CrossRef45
Seongman Kang, Sunghoi Hong. (2011) Prediction of personalized drugs based on genetic variations provided by DNA sequencing technologies. Genes & Genomics 33:6, 591-603
CrossRef46
Shinichiro Uchiyama. (2011) Clopidogrel Resistance: Identifying and Overcoming a Barrier to Effective Antiplatelet Treatment. Cardiovascular Therapeutics 29:6, e100-e111
CrossRef47
Thomas Gremmel, Christoph W. Kopp, Deddo Moertl, Daniela Seidinger, Renate Koppensteiner, Simon Panzer, Christine Mannhalter, Sabine Steiner. (2011) Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests. Thrombosis Research
CrossRef48
A. D. TSELEPIS, M. E. TSOUMANI, K. I. KALANTZI, A. A. DIMITRIOU, C. C. TELLIS, I. A. GOUDEVENOS. (2011) Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy. Journal of Thrombosis and Haemostasis 9:12, 2371-2378
CrossRef49
Kyung Woo Park, Ki-Hyun Jeon, Si-Hyuk Kang, Il-Young Oh, Hyun-Jai Cho, Hae-Young Lee, Hyun-Jae Kang, Sue K. Park, Bon-Kwon Koo, Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim. (2011) Clinical Outcomes of High On-Treatment Platelet Reactivity in Koreans Receiving Elective Percutaneous Coronary Intervention (from Results of the CROSS VERIFY Study). The American Journal of Cardiology 108:11, 1556-1563
CrossRef50
A. D. Michelson. (2011) Advances in Antiplatelet Therapy. Hematology 2011:1, 62-69
CrossRef51
J. Silvain, G. Cayla, J.-S. Hulot, J. Finzi, M. Kerneis, S. A. O'Connor, A. Bellemain-Appaix, O. Barthelemy, F. Beygui, J.-P. Collet, G. Montalescot. (2011) High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. European Heart Journal
CrossRef52
Tsukasa Ohmori, Yuichiro Yano, Asuka Sakata, Tomokazu Ikemoto, Masahisa Shimpo, Seiji Madoiwa, Takaaki Katsuki, Jun Mimuro, Kazuyuki Shimada, Kazuomi Kario, Yoichi Sakata. (2011) Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy. Thrombosis Research
CrossRef53
Charles V. Pollack, Gerard X. Brogan, Marc Cohen, Deborah Diercks, Cindy Grines, Timothy D. Henry, Neal S. Kleiman, Robert P. Giugliano. (2011) ED to catheterization laboratory: a roundtable integrating trials with practice. The American Journal of Emergency Medicine 29:9, 1203-1216
CrossRef54
Chee Tang Chin, Tracy Y. Wang, Kevin J. Anstrom, Baojin Zhu, Jen-Fue Maa, John C. Messenger, Kelley A. Ryan, Linda Davidson-Ray, Marjorie Zettler, Mark B. Effron, Daniel B. Mark, Eric D. Peterson. (2011) Treatment with Adenosine Diphosphate Receptor Inhibitors—Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study design: Expanding the paradigm of longitudinal observational research. American Heart Journal 162:5, 844-851
CrossRef55
Robert A. Henderson, Adam D. Timmis. (2011) Almanac 2011: Stable coronary artery disease. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa de Cardiologia (English Edition) 30:11, 869-878
CrossRef56
Thomas Gremmel, Christoph W. Kopp, Daniela Seidinger, Renate Koppensteiner, Simon Panzer, Raute Sunder-Plassmann, Christine Mannhalter, Sabine Steiner. (2011) Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests. International Journal of Cardiology
CrossRef57
Robert A. Henderson, Adam D. Timmis. (2011) Almanac 2011: stable coronary artery disease. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa de Cardiologia 30:11, 869-878
CrossRef58
Sidney C. Smith, Emelia J. Benjamin, Robert O. Bonow, Lynne T. Braun, Mark A. Creager, Barry A. Franklin, Raymond J. Gibbons, Scott M. Grundy, Loren F. Hiratzka, Daniel W. Jones, Donald M. Lloyd-Jones, Margo Minissian, Lori Mosca, Eric D. Peterson, Ralph L. Sacco, John Spertus, James H. Stein, Kathryn A. Taubert. (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Journal of the American College of Cardiology 58:23, 2432-2446
CrossRef59
Daniela D. Vargens, Maria-Luiza Petzl-Erler, Guilherme Suarez-Kurtz. (2011) Distribution of CYP2C Polymorphisms in an Amerindian Population of Brazil. Basic & Clinical Pharmacology & Toxicologyno-no
CrossRef60
Aldona Kubica, Marek Kozinski, Grzegorz Grzesk, Tomasz Fabiszak, Eliano Pio Navarese, Aleksander Goch. (2011) Genetic determinants of platelet response to clopidogrel. Journal of Thrombosis and Thrombolysis 32:4, 459-466
CrossRef61
Martin Jenkins, Aiden Flynn, Trevor Smart, Chris Harbron, Tony Sabin, Jayantha Ratnayake, Paul Delmar, Athula Herath, Philip Jarvis, James Matcham, . (2011) A statistician's perspective on biomarkers in drug development. Pharmaceutical Statistics 10:6, 494-507
CrossRef62
Antonio Tello-Montoliu, Eva Jover, Francisco Marín, Agustina Bernal, María L. Lozano, Beatriz Sánchez-Vega, Francisco J. Pastor, José A. Hurtado, Mariano Valdés, Vicente Vicente, José Rivera. (2011) Influence of CYP2C19 Polymorphisms in Platelet Reactivity and Prognosis in an Unselected Population of Non ST Elevation Acute Coronary Syndrome. Revista Española de Cardiología (English Edition)
CrossRef63
Isabelle Djaffar Jureidini, Nabil Chamseddine, Sose Keleshian, Rania Naoufal, Laila Zahed, Noha Hakime. (2011) Prevalence of CYP2C19 polymorphisms in the Lebanese population. Molecular Biology Reports 38:8, 5449-5452
CrossRef64
Pamela Moceri, Denis Doyen, Pierre Cerboni, Emile Ferrari. (2011) Doubling the dose of Clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. Thrombosis Research 128:5, 458-462
CrossRef65
Satyendra Giri. (2011) Optimal treatment of ACS patients: Issues and considerations for upstream antiplatelet therapy. International Journal of Cardiology
CrossRef66
David H. Fitchett, Pierre Theroux, James M. Brophy, Warren J. Cantor, Jafna L. Cox, Milan Gupta, Heather Kertland, Shamir R. Mehta, Robert C. Welsh, Shaun G. Goodman. (2011) Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 1: Non-ST–Segment Elevation ACS. Canadian Journal of Cardiology 27:6, S387-S401
CrossRef67
Antonio Tello-Montoliu, Eva Jover, Francisco Marín, Agustina Bernal, María L. Lozano, Beatriz Sánchez-Vega, Francisco J. Pastor, José A. Hurtado, Mariano Valdés, Vicente Vicente, José Rivera. (2011) Influencia de los polimorfismos de CYP2C19 en la reactividad plaquetaria y el pronóstico en una población no seleccionada de pacientes con síndrome coronario agudo sin elevación del ST. Revista Española de Cardiología
CrossRef68
Renier Myburgh, Warren E. Hochfeld, Tyren M. Dodgen, James Ker, Michael S. Pepper. (2011) Cardiovascular pharmacogenetics. Pharmacology & Therapeutics
CrossRef69
Y. Li, H.-L. Tang, Y.-F. Hu, H.-G. Xie. (2011) The Gain-of-Function Variant Allele CYP2C19*17: A Double-Edged Sword Between Thrombosis and Bleeding in Clopidogrel-Treated Patients. Journal of Thrombosis and Haemostasisno-no
CrossRef70
J. J. Swen, T. Straaten, J. A. M. Wessels, M. L. Bouvy, E. E. W. Vlassak, W. J. J. Assendelft, H.-J. Guchelaar. (2011) Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19. European Journal of Clinical Pharmacology
CrossRef71
Felix W. Frueh. (2011) Considerations for safety pharmacogenetics in clinical practice. Drug Discovery Today 16:19-20, 898-901
CrossRef72
Thomas Gremmel, Sabine Steiner, Daniela Seidinger, Renate Koppensteiner, Simon Panzer, Christoph W. Kopp. (2011) The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Thrombosis Research 128:4, 352-357
CrossRef73
T Simon, P G Steg, L Becquemont, C Verstuyft, S Kotti, F Schiele, E Ferrari, E Drouet, G Grollier, N Danchin. (2011) Effect of Paraoxonase-1 Polymorphism on Clinical Outcomes in Patients Treated With Clopidogrel After an Acute Myocardial Infarction. Clinical Pharmacology & Therapeutics 90:4, 561-567
CrossRef74
Jean-Sébastien Hulot, Jean-Philippe Collet, Gilles Montalescot. (2011) Thienopyridine-Associated Drug-Drug Interactions: Pharmacologic Mechanisms and Clinical Relevance. Current Cardiology Reports 13:5, 451-458
CrossRef75
Stephen D. Wiviott, Nihar Desai, Sabina A. Murphy, Guiseppe Musumeci, Michael Ragosta, Elliott M. Antman, Eugene Braunwald. (2011) Efficacy and Safety of Intensive Antiplatelet Therapy With Prasugrel from TRITON-TIMI 38 in a Core Clinical Cohort Defined by Worldwide Regulatory Agencies. The American Journal of Cardiology 108:7, 905-911
CrossRef76
José Antonio Páramo. (2011) Nueva era en la terapia antiplaquetar basada en los resultados de ensayos clínicos recientes. Medicina Clínica 137:11, 504-508
CrossRef77
Theodoros Lillis, Antonios Ziakas, Konstantinos Koskinas, Anastasios Tsirlis, George Giannoglou. (2011) Safety of Dental Extractions During Uninterrupted Single or Dual Antiplatelet Treatment. The American Journal of Cardiology 108:7, 964-967
CrossRef78
A. M. HARMSZE, J. W. VAN WERKUM, P. C. SOUVEREIN, N. J. BREET, H. J. BOUMAN, C. M. HACKENG, H. J. T. RUVEN, J. M. TEN BERG, O. H. KLUNGEL, A. DE BOER, V. H. M. DENEER. (2011) Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. Journal of Thrombosis and Haemostasis 9:10, 1892-1901
CrossRef79
Terry K. W. Ma, Yat-Yin Lam, Victoria P. Tan, Bryan P. Yan. (2011) Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?. British Journal of Clinical Pharmacology 72:4, 697-706
CrossRef80
Tong Yin, Toshiyuki Miyata. (2011) Pharmacogenomics of clopidogrel: Evidence and perspectives. Thrombosis Research 128:4, 307-316
CrossRef81
Arthur W. Bracey, Meredith A. Reyes, Alice J. Chen, Maryam Bayat, Paul M. Allison. (2011) How do we manage patients treated with antithrombotic therapy in the perioperative interval. Transfusion 51:10, 2066-2077
CrossRef82
Ronald J. Dick, Anthony E. Dear, Keith A. Byron. (2011) Clopidogrel Resistance: Case reports of CYP2C19 gene variants in suspected coronary stent thrombosis. Heart, Lung and Circulation 20:10, 657-658
CrossRef83
Helmi Lutsep. (2011) Update on selecting and adjusting antiplatelet therapy for prevention of noncardiogenic, recurrent ischemic stroke. Expert Review of Cardiovascular Therapy 9:10, 1295-1303
CrossRef84
J P Lewis, A S Fisch, K Ryan, J R O'Connell, Q Gibson, B D Mitchell, H Shen, K Tanner, R B Horenstein, R Pakzy, U S Tantry, K P Bliden, P A Gurbel, A R Shuldiner. (2011) Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response. Clinical Pharmacology & Therapeutics 90:4, 568-574
CrossRef85
Axel Labriolle, Jean Philippe Doazan, Gilles Lemesle, Laurent Bonello. (2011) Genotypic and Phenotypic Assessment of Platelet Function and Response to P2Y12 Antagonists. Current Cardiology Reports 13:5, 439-450
CrossRef86
Fei-Yuan Hsiao, C. Daniel Mullins, Yu-Wen Wen, Weng-Foung Huang, Pei-Fen Chen, Yi-Wen Tsai. (2011) Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. Pharmacoepidemiology and Drug Safety 20:10, 1043-1049
CrossRef87
Grigorios I. Leontiadis, Yuhong Yuan, Colin W. Howden. (2011) The Interaction Between Proton Pump Inhibitors and Clopidogrel and Upper Gastrointestinal Bleeding. Gastrointestinal Endoscopy Clinics of North America 21:4, 637-656
CrossRef88
N L Pereira, R M Weinshilboum. (2011) The Impact of Pharmacogenomics on the Management of Cardiac Disease. Clinical Pharmacology & Therapeutics 90:4, 493-495
CrossRef89
Nalyaka Sambu, Nick Curzen. (2011) Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations. British Journal of Clinical Pharmacology 72:4, 683-696
CrossRef90
Frederieke H van der Baan, Olaf H Klungel, Antoine CG Egberts, Hubert G Leufkens, Diederick E Grobbee, Kit CB Roes, Mirjam J Knol. (2011) Pharmacogenetics in randomized controlled trials: considerations for trial design. Pharmacogenomics 12:10, 1485-1492
CrossRef91
Neena S. Abraham. (2011) Prescribing proton pump inhibitor and clopidogrel together. Current Opinion in Gastroenterology 27:6, 558-564
CrossRef92
K-H Jung, K Chu, S-T Lee, H-J Yoon, J-Y Chang, W-S Nam, S-H Yoon, J-Y Cho, K-S Yu, I-J Jang, M Kim, S K Lee, J-K Roh. (2011) Prolonged Use of Aspirin Alters Human and Rat Intestinal Cells and Thereby Limits the Absorption of Clopidogrel. Clinical Pharmacology & Therapeutics 90:4, 612-619
CrossRef93
B.H.A. Rahden, M. Scheurlen, J. Filser, H.J. Stein, C.-T. Germer. (2011) Neu erkannte Nebenwirkungen von Protonenpumpeninhibitoren. Der Chirurg
CrossRef94
Thomas Cuisset, Pierre-Emmanuel Morange, Jacques Quilici, Jean Louis Bonnet, Christian Gachet, Marie-Christine Alessi. (2011) Paraoxonase-1 and clopidogrel efficacy. Nature Medicine 17:9, 1039-1039
CrossRef95
Gianluca Campo, Matteo Miccoli, Matteo Tebaldi, Jlenia Marchesini, Luca Fileti, Monia Monti, Marco Valgimigli, Roberto Ferrari. (2011) Genetic determinants of on-clopidogrel high platelet reactivity. Platelets 22:6, 399-407
CrossRef96
Michael A. Gaglia, Rebecca Torguson, Rajbabu Pakala, Zhenyi Xue, Gabriel Sardi, Michael Mahmoudi, William O. Suddath, Kenneth M. Kent, Lowell F. Satler, Augusto D. Pichard, Ron Waksman. (2011) Relation of Body Mass Index to On-Treatment (Clopidogrel + Aspirin) Platelet Reactivity. The American Journal of Cardiology 108:6, 766-771
CrossRef97
Henk Visscher, Ursula Amstutz, Johanna Sistonen, Colin J Ross, Michael R Hayden, Bruce C Carleton. (2011) Pharmacogenomics of Cardiovascular Drugs and Adverse Effects in Pediatrics. Journal of Cardiovascular Pharmacology 58:3, 228-239
CrossRef98
Willibald Hochholzer, Dietmar Trenk, Jessica L. Mega, Tanja Morath, Christian Stratz, Christian M. Valina, Michelle L. O'Donoghue, Isabell Bernlochner, Charles F. Contant, Jianping Guo, Marc S. Sabatine, Albert Schömig, Franz-Josef Neumann, Adnan Kastrati, Stephen D. Wiviott, Dirk Sibbing. (2011) Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. American Heart Journal 162:3, 518-526.e5
CrossRef99
Antonella Boni, Valentina Riva, Elisabetta Galloni, Francesco Perini. (2011) Attività piastrinica residua e fallimento clinico della profilassi antitrombotica nell’attacco ischemico cerebrale acuto. La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine 7:3, 163-169
CrossRef100
David R. Holmes, Jeffrey A. Becker, Christopher B. Granger, Marian C. Limacher, Robert Lee Page, Cathy Sila, Joseph P. Drozda, Joseph G. Cacchione, Blair D. Erb, Robert A. Harrington, Jerry D. Kennett, Harlan M. Krumholz, Frederick A. Masoudi, Eric D. Peterson, Athena Poppas, David J. Sahn, Mark L. Sanz, David M. Shahian, John R. Windle, Janet F. Wyman. (2011) ACCF/AHA 2011 Health Policy Statement on Therapeutic Interchange and Substitution. Journal of the American College of Cardiology 58:12, 1287-1307
CrossRef101
John J. Ricotta, Ali AbuRahma, Enrico Ascher, Mark Eskandari, Peter Faries, Brajesh K. Lal. (2011) Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery 54:3, e1-e31
CrossRef102
Nadia Paarup Dridi, Lene Holmvang, Peter Clemmensen. (2011) Oral antiplatelet agents in ischemic heart disease: a review of the latest clinical evidence. Clinical Investigation 1:9, 1315-1328
CrossRef103
Huijuan Wang, Raymond A. Kim, Dongxu Sun, Yiwen Gao, Hao Wang, Juanli Zhu, Chao Chen. (2011) Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay. Xenobiotica 41:9, 826-835
CrossRef104
Tariq Ahmad, Deepak Voora, Richard C. Becker. (2011) The pharmacogenetics of antiplatelet agents: towards personalized therapy?. Nature Reviews Cardiology 8:10, 560-571
CrossRef105
Xiang Xue, Likun Gong, Xinming Qi, Yuanfeng Wu, Guozhen Xing, Jun Yao, Yang Luan, Ying Xiao, Yan Li, Xiongfei Wu, Min Chen, Jun Gu, Jin Ren. (2011) Knockout of hepatic P450 reductase aggravates triptolide-induced toxicity. Toxicology Letters 205:1, 47-54
CrossRef106
Kiran Musunuru. (2011) Current Role of Pharmacogenomics in Cardiovascular Medicine. Current Treatment Options in Cardiovascular Medicine 13:4, 302-312
CrossRef107
T. Burkard, C. A. Kaiser, H. Brunner-La Rocca, S. Osswald, M. E. Pfisterer, R. V. Jeger, . (2011) Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. Journal of Internal Medicineno-no
CrossRef108
Lawrence Rajan, David J. Moliterno. (2011) Beyond Aspirin and Clopidogrel: Is There a Need for Additional Antiplatelet Therapy in ACS?. Current Cardiology Reports 13:4, 303-311
CrossRef109
S A Scott, K Sangkuhl, E E Gardner, C M Stein, J-S Hulot, J A Johnson, D M Roden, T E Klein, A R Shuldiner. (2011) Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clinical Pharmacology & Therapeutics 90:2, 328-332
CrossRef110
George Kassimis, Periklis Davlouros, Ioanna Xanthopoulou, Eleana F. Stavrou, Aglaia Athanassiadou, Dimitrios Alexopoulos. (2011) CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thrombosis Research
CrossRef111
Seiji Takashio, Seiji Hokimoto, Koichi Kaikita, Kazuteru Fujimoto, Ikuo Misumi, Kazuko Nakagawa, Hisao Ogawa. (2011) Repetitive early stent thrombosis in a patient with the CYP2C19*3/*3 genotype. Journal of Cardiology Cases 4:1, e16-e19
CrossRef112
T Simon, D L Bhatt, L Bergougnan, C Farenc, K Pearson, L Perrin, E Vicaut, F LaCreta, F Hurbin, M Dubar. (2011) Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects. Clinical Pharmacology & Therapeutics 90:2, 287-295
CrossRef113
Elise Camilleri, Laurent Jacquin, Franck Paganelli, Laurent Bonello. (2011) Personalized Antiplatelet Therapy: Review of the Latest Clinical Evidence. Current Cardiology Reports 13:4, 296-302
CrossRef114
Isabell Bernlochner, Robert A Byrne, Adnan Kastrati, Dirk Sibbing. (2011) The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Expert Review of Cardiovascular Therapy 9:8, 999-1014
CrossRef115
Sandra L. Close. (2011) Clopidogrel pharmacogenetics: metabolism and drug interactions. Drug Metabolism and Drug Interactions 26:2, 45-51
CrossRef116
Omair Yousuf, Deepak L. Bhatt. (2011) The evolution of antiplatelet therapy in cardiovascular disease. Nature Reviews Cardiology 8:10, 547-559
CrossRef117
Hisao Ogawa, Seiji Hokimoto, Koichi Kaikita, Koichiro Yamamoto, Tadasuke Chitose, Takamichi Ono, Kenichi Tsujita. (2011) Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: Focus on adenosine diphosphate receptor inhibitors. Journal of Cardiology 58:1, 6-17
CrossRef118
Jean Szymezak, Caroline Moreau, Marie-Anne Loriot, Eric Durand, Hubert Van Viet, Michel Desnos, Pascale Gaussem. (2011) High on-clopidogrel platelet reactivity: Genotyping Can help to optimize antiplatelet treatment. Thrombosis Research 128:1, 92-95
CrossRef119
Carlos Felipe Barrera-Ramírez, Luis Ramón Pineda-Pompa, Carlos E. Guzmán-Rodríguez. (2011) Sobre el metabolismo de prasugrel. Revista Española de Cardiología 64:7, 629
CrossRef120
B. S. COLLER. (2011) Historical perspective and future directions in platelet research. Journal of Thrombosis and Haemostasis 9, 374-395
CrossRef121
Kevin P. Bliden, Udaya S. Tantry, Robert F. Storey, Young-Hoon Jeong, Martin Gesheff, Cheryl Wei, Paul A. Gurbel. (2011) The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies. American Heart Journal 162:1, 160-165
CrossRef122
Guang-Ming Tan, Yat-Yin Lam, Bryan P. Yan. (2011) Novel Platelet ADP P2Y12 Inhibitors in the Treatment of Acute Coronary Syndrome. Cardiovascular Therapeuticsno-no
CrossRef123
Carlos Felipe Barrera-Ramírez, Luis Ramón Pineda-Pompa, Carlos E. Guzmán-Rodríguez. (2011) On the Metabolism of Prasugrel. Revista Española de Cardiología (English Edition) 64:7, 629
CrossRef124
D. Sibbing, W. Koch, S. Massberg, R. A. Byrne, J. Mehilli, S. Schulz, K. Mayer, I. Bernlochner, A. Schomig, A. Kastrati. (2011) No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. European Heart Journal 32:13, 1605-1613
CrossRef125
Zeshan Qureshi, Alex R. Hobson. (2011) Clopidogrel “Resistance”: Where are We Now?. Cardiovascular Therapeuticsno-no
CrossRef126
Dominick J. Angiolillo, Esther Bernardo, Martina Zanoni, David Vivas, Piera Capranzano, Giovanni Malerba, Davide Capodanno, Paola Prandini, Alessandra Pasquali, Elisabetta Trabetti, Manel Sabaté, Pilar Jimenez-Quevedo, Jose L. Ferreiro, Masafumi Ueno, Theodore A. Bass, Pier Franco Pignatti, Antonio Fernandez-Ortiz, Carlos Macaya. (2011) Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Journal of the American College of Cardiology 58:1, 30-39
CrossRef127
Masamichi Iwasaki, Takahiro Sawada, Toshiro Shinke, Hiroshi Okamoto, Su-sik Kim, Junya Shite, Ken-ichi Hirata, Mitsuhiro Yokoyama. (2011) Repeated intra-stent thrombus formation in a patient with acute coronary syndrome due to poor responsiveness to clopidogrel may be associated with cytochrome P-450 2C19*2 polymorphism. Journal of Cardiology Cases 3:3, e123-e128
CrossRef128
F Sofi, B Giusti, R Marcucci, A M Gori, R Abbate, G F Gensini. (2011) Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. The Pharmacogenomics Journal 11:3, 199-206
CrossRef129
Daniel J. Crespin, Jerome J. Federspiel, Andrea K. Biddle, Daniel E. Jonas, Joseph S. Rossi. (2011) Ticagrelor versus Genotype-Driven Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Value in Health 14:4, 483-491
CrossRef130
Michael A. Pacanowski, Issam Zineh. (2011) Pharmacogenomic strategies in drug safety. Drug Discovery Today: Therapeutic Strategies
CrossRef131
Vangelis G Manolopoulos, Bryan Dechairo, Alain Huriez, Alexander Kühn, Adrián LLerena, Ron H van Schaik, Kiang-Teck J Yeo, Georgia Ragia, Gerard Siest. (2011) Pharmacogenomics and personalized medicine in clinical practice. Pharmacogenomics 12:5, 597-610
CrossRef132
Samir B. Damani, Eric J. Topol. (2011) Emerging Genomic Applications in Coronary Artery Disease. JACC: Cardiovascular Interventions 4:5, 473-482
CrossRef133
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). Journal of the American College of Cardiology 57:19, 1920-1959
CrossRef134
M. Oberhänsli, S. Puricel, M. Togni, S. Cook. (2011) Koronare Stent-Thrombosen. Herz 36:3, 241-253
CrossRef135
Andrew J Howe, James A Shand, Ian BA Menown. (2011) Advances in cardiology: clinical trial update. Future Cardiology 7:3, 299-310
CrossRef136
Christine C. Lee, Gwendolyn A. McMillin, Nikolina Babic, Roberta Melis, Kiang-Teck J. Yeo. (2011) Evaluation of a CYP2C19 genotype panel on the GenMark eSensor® platform and the comparison to the Autogenomics Infiniti™ and Luminex CYP2C19 panels. Clinica Chimica Acta 412:11-12, 1133-1137
CrossRef137
Ali J Marian. (2011) Medical DNA sequencing. Current Opinion in Cardiology 26:3, 175-180
CrossRef138
J. Douglas Kirk, Michael Kontos, Deborah B. Diercks. (2011) Upstream treatment of acute coronary syndrome in the ED. The American Journal of Emergency Medicine 29:4, 446-456
CrossRef139
Stefan Lischke, David J Schneider. (2011) Recent developments in the use of antiplatelet agents to prevent cardiovascular events. Future Cardiology 7:3, 403-413
CrossRef140
Bernadetta Chyrchel, Andrzej Surdacki, Michał Chyrchel, Dariusz Dudek, Jacek S. Dubiel. (2011) Separate dosing of clopidogrel and omeprazole may improve platelet inhibition on dual antiplatelet therapy. International Journal of Cardiology 149:1, 124-125
CrossRef141
Kengo Tsukahara, Kazuo Kimura, Satoshi Morita, Toshiaki Ebina, Masami Kosuge, Kiyoshi Hibi, Noriaki Iwahashi, Mitsuaki Endo, Nobuhiko Maejima, Teruyasu Sugano, Satoshi Umemura. (2011) Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects. Journal of Cardiology 57:3, 275-282
CrossRef142
Jane P. F. Bai, Mike Pacanowski, Atiqur Rahman, Lawrence L. Lesko. 2011. The Impact of Pharmacogenetics on the Clinical Outcomes of Prodrugs. , 453-481.
CrossRef143
Dominick J. Angiolillo, Masafumi Ueno. (2011) Optimizing Platelet Inhibition in Clopidogrel Poor Metabolizers. JACC: Cardiovascular Interventions 4:4, 411-414
CrossRef144
ROBERT P. GIUGLIANO, CHARLES V POLLACK Jr., GERARD X BROGAN Jr., MARC COHEN, DEBORAH B DIERCKS, CINDY L GRINES, TIMOTHY D. HENRY, NEAL S KLEIMAN. (2011) Acute Coronary Syndromes: From the Emergency Department to the Catheterization Laboratory-Integrating Evidence from Recent ACS/NSTEMI Trials into Clinical Practice: An Evidence-Based Review of Recent Clinical Trial Results and Report on a Roundtable Discu. Journal of Interventional Cardiology 24:2, 119-136
CrossRef145
B. R. Disney, R. D. S. Watson, A. D. Blann, G. Y. H. Lip, M. R. Anderson. (2011) Review article: proton pump inhibitors with clopidogrel - evidence for and against a clinically-important interaction. Alimentary Pharmacology & Therapeutics 33:7, 758-767
CrossRef146
Michelle T. Martin, Sarah A. Spinler, Edith A. Nutescu. (2011) Emerging Antiplatelet Therapies in Percutaneous Coronary Intervention: A Focus on Prasugrel. Clinical Therapeutics 33:4, 425-442
CrossRef147
Dimitrios Alexopoulos, Gerasimos Dimitropoulos, Periklis Davlouros, Ioanna Xanthopoulou, George Kassimis, Eleana F. Stavrou, George Hahalis, Aglaia Athanassiadou. (2011) Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High-Dose (150-mg) Clopidogrel. JACC: Cardiovascular Interventions 4:4, 403-410
CrossRef148
Udaya S. Tantry, Dean J. Kereiakes, Paul A. Gurbel. (2011) Clopidogrel and Proton Pump Inhibitors. JACC: Cardiovascular Interventions 4:4, 365-380
CrossRef149
Edward Sheen, George Triadafilopoulos. (2011) Adverse Effects of Long-Term Proton Pump Inhibitor Therapy. Digestive Diseases and Sciences 56:4, 931-950
CrossRef150
Charles Brown, Brijen Joshi, Nauder Faraday, Ashish Shah, David Yuh, Jeffrey J. Rade, Charles W. Hogue. (2011) Emergency Cardiac Surgery in Patients with Acute Coronary Syndromes. Anesthesia & Analgesia 112:4, 777-799
CrossRef151
In-Suk Kim, Young-Hoon Jeong, Yongwhi Park, Ki-Soo Park, Seong-Eun Yun, Jeong-Rang Park, Seok-Jae Hwang, Eun-Ha Koh, Choong Hwan Kwak, Jin-Yong Hwang, Sunjoo Kim. (2011) Platelet Inhibition by Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients With Acute Myocardial Infarction According to Cytochrome P450 2C19 Genotype. JACC: Cardiovascular Interventions 4:4, 381-391
CrossRef152
Feero, W. Gregory, Guttmacher, Alan E., , Wang, Liewei, McLeod, Howard L., Weinshilboum, Richard M., . (2011) Genomics and Drug Response. New England Journal of Medicine 364:12, 1144-1153
Full Text153
Pete P. Fong, Emily Blake Jackson, Keith B. Churchwell, Robin Steaban, John M. Starmer, Daniel C. Johnson, Julie D. McNeil, Zachary W. Klint, Sonia L. Scalf, Carol M. Parsons, Susan Cortez, Donna Christensen, Tina French, John A. McPherson. (2011) Acute Coronary Syndrome Pathways. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 10:1, 1-8
CrossRef154
Edwin Ho, Ravinay Bhindi, Euan A. Ashley, Gemma A. Figtree. (2011) Genetic Analysis in Cardiovascular Disease. Cardiology in Review 19:2, 81-89
CrossRef155
A L Beitelshees, R B Horenstein, M R Vesely, M R Mehra, A R Shuldiner. (2011) Pharmacogenetics and Clopidogrel Response in Patients Undergoing Percutaneous Coronary Interventions. Clinical Pharmacology & Therapeutics 89:3, 455-459
CrossRef156
Hong-Guang Xie, Jian-Jun Zou, Zuo-Ying Hu, Jun-Jie Zhang, Fei Ye, Shao-Liang Chen. (2011) Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond. Pharmacology & Therapeutics 129:3, 267-289
CrossRef157
S A Scott, S Martis, I Peter, Y Kasai, R Kornreich, R J Desnick. (2011) Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. The Pharmacogenomics Journal
CrossRef158
Dale Halsey Lea, Heather Skirton, Catherine Y. Read, Janet K. Williams. (2011) Implications for Educating the Next Generation of Nurses on Genetics and Genomics in the 21st Century. Journal of Nursing Scholarship 43:1, 3-12
CrossRef159
Lisa Padgett, Shanna O'Connor, Mary Roederer, Howard McLeod, Stefanie Ferreri. (2011) Pharmacogenomics in a community pharmacy: ACT now. Journal of the American Pharmacists Association 51:2, 189-193
CrossRef160
Samir B. Damani, Eric J. Topol. (2011) Emerging clinical applications in cardiovascular pharmacogenomics. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 3:2, 206-215
CrossRef161
B. Gellen, E. Teiger. (2011) Thrombose de stent. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2011:196, 31-34
CrossRef162
Philip Urban, Alexandre Abizaid, Adrian Banning, Antonio L. Bartorelli, Ana Cebrian Baux, Vladimír Džavík, Stephen Ellis, Runlin Gao, David Holmes, Myung Ho Jeong, Victor Legrand, Franz-Josef Neumann, Maria Nyakern, Christian Spaulding, Stephen Worthley. (2011) Stent Thrombosis and Bleeding Complications After Implantation of Sirolimus-Eluting Coronary Stents in an Unselected Worldwide Population. Journal of the American College of Cardiology 57:13, 1445-1454
CrossRef163
Ping–I. Hsu, Kwok–Hung Lai, Chun–Peng Liu. (2011) Esomeprazole With Clopidogrel Reduces Peptic Ulcer Recurrence, Compared With Clopidogrel Alone, in Patients With Atherosclerosis. Gastroenterology 140:3, 791-798.e2
CrossRef164
Paul A. Gurbel, Alan R. Shuldiner, Kevin P. Bliden, Kathaleen Ryan, Ruth E. Pakyz, Udaya S. Tantry. (2011) The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. American Heart Journal 161:3, 598-604
CrossRef165
Bo Jin, Huan-Chun Ni, Wei Shen, Jian Li, Hai-Ming Shi, Yong Li. (2011) Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Molecular Biology Reports 38:3, 1697-1702
CrossRef166
Ankie M. Harmsze, Jochem W. Van Werkum, Fulya Moral, Jurriën M. Ten Berg, Christian M. Hackeng, Olaf H. Klungel, Anthonius De Boer, Vera H. M. Deneer. (2011) Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets 22:2, 98-102
CrossRef167
Jihe Lim, Sang Hyun Suh, Kyung-Yul Lee, Chang Ki Hong, Seoung Woo Park. (2011) Endovascular Treatment of Iatrogenic Intracranial Pseudoaneurysm Following Stent Angioplasty. Journal of Neuroimagingno-no
CrossRef168
(2011) CYP2C19 Genotype and Outcomes of Clopidogrel Treatment. New England Journal of Medicine 364:5, 481-482
Full Text169
Bas JM Peters, Ankie M Harmsze, Jurriën M ten Berg, Anke-Hilse Maitland-van der Zee, Mathieu M Tjoeng, Anthonius de Boer, Vera HM Deneer. (2011) CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel. Pharmacogenomics 12:2, 141-144
CrossRef170
J. Li, L. Zhang, H. Zhou, M. Stoneking, K. Tang. (2011) Global patterns of genetic diversity and signals of natural selection for human ADME genes. Human Molecular Genetics 20:3, 528-540
CrossRef171
Fiona Foo, Keith G Oldroyd. (2011) Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. Biomarkers in Medicine 5:1, 9-30
CrossRef172
Chiara Gentilomo, Yuan-Shung Huang, Leslie Raffini. (2011) Significant Increase in Clopidogrel Use Across U.S. Children’s Hospitals. Pediatric Cardiology 32:2, 167-175
CrossRef173
Dimitrios Alexopoulos. (2011) CYP2C19*2 allele: guiding medication choice after percutaneous coronary intervention. Interventional Cardiology 3:1, 1-4
CrossRef174
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Journal of the American College of Cardiology 57:8, e16-e94
CrossRef175
Richard Hall, C. David Mazer. (2011) Antiplatelet Drugs. Anesthesia & Analgesia 112:2, 292-318
CrossRef176
, Bob Wilffert, Jesse Swen, Hans Mulder, Daan Touw, Anke-Hilse Maitland-Van der Zee, Vera Deneer. (2011) From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. International Journal of Clinical Pharmacy 33:1, 3-9
CrossRef177
Joseph A Jakubowski. (2011) Beyond platelet functional testing: value in the aggregate. Biomarkers in Medicine 5:1, 5-8
CrossRef178
Megan M. Donohue, David L. Tirschwell. (2011) Implications of Pharmacogenetic Testing for Patients Taking Warfarin or Clopidogrel. Current Neurology and Neuroscience Reports 11:1, 52-60
CrossRef179
Tobias Gerhard. (2011) Clopidogrel and proton pump inhibitors: a clinically meaningful interaction?. Pharmacoepidemiology and Drug Safety 20:2, 214-218
CrossRef180
A Maeda, H Ando, T Asai, H Ishiguro, N Umemoto, M Ohta, M Morishima, A Sumida, T Kobayashi, K Hosohata, K Ushijima, A Fujimura. (2011) Differential Impacts of CYP2C19 Gene Polymorphisms on the Antiplatelet Effects of Clopidogrel and Ticlopidine. Clinical Pharmacology & Therapeutics 89:2, 229-233
CrossRef181
Joseph A. Jakubowski, Jeffrey S. Riesmeyer, Sandra L. Close, Amy G. Leishman, David Erlinge. (2011) TRITON and Beyond: New Insights into the Profile of Prasugrel. Cardiovascular Therapeuticsno-no
CrossRef182
Arwa Hassan, Jürgen Burhenne, Klaus-Dieter Riedel, Johanna Weiss, Gerd Mikus, Walter E Haefeli, David Czock. (2011) Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 33:1, 86-93
CrossRef183
G. L. MENDOLICCHIO, D. ZAVALLONI, M. BACCI, E. CORRADA, M. MARCONI, C. LODIGIANI, P. PRESBITERO, L. ROTA, Z. M. RUGGERI. (2011) Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood. Journal of Thrombosis and Haemostasis 9:2, 373-382
CrossRef184
M. Silvano, C. F. Zambon, G. Rosa, M. Plebani, V. Pengo, M. Napodano, R. Padrini. (2011) A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. Journal of Thrombosis and Thrombolysis 31:2, 233-234
CrossRef185
Jean-Sébastien Hulot, Jean-Philippe Collet, Gilles Montalescot. (2011) Genetic substudy of the PLATO trial. The Lancet 377:9766, 637
CrossRef186
Keiichiro YAMANE, Hisanori HORIUCHI. (2011) 5. Drug Interaction between Clopidogrel and Proton Pump Inhibitors. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 42:6, 383-388
CrossRef187
Laurent Becquemont, Ana Alfirevic, Ursula Amstutz, Hiltrud Brauch, Evelyne Jacqz-Aigrain, Pierre Laurent-Puig, Miguel A Molina, Mikko Niemi, Matthias Schwab, Andrew A Somogyi, Eric Thervet, Anke-Hilse Maitland-van der Zee, André BP van Kuilenburg, Ron HN van Schaik, Céline Verstuyft, Mia Wadelius, Ann K Daly. (2011) Practical recommendations for pharmacogenomics-based prescription: 2010 ESF–UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 12:1, 113-124
CrossRef188
J. E. van Loon, P. P. T. de Jaegere, H. Ulrichts, H. H. D. M. van Vliet, M. P. M. de Maat, P. G. de Groot, M. L. Simoons, F. W. G. Leebeek. (2011) The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention. Thrombosis and Haemostasis 106:1, 165-171
CrossRef189
Akimitsu MAEDA, Hitoshi ANDO, Takashi KOBAYASHI, Toru ASAI, Hisaaki ISHIGURO, Norio UMEMOTO, Keiko HOSOHATA, Kentarou USHIJIMA, Akio FUJIMURA. (2011) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 42:3, 151-152
CrossRef190
Eric J Topol, Nicholas J Schork. (2011) Catapulting clopidogrel pharmacogenomics forward. Nature Medicine 17:1, 40-41
CrossRef191
Akinori Sairaku, Yukiko Nakano, Shin Eno, Tatsuya Hondo, Keiji Matsuda, Tomohiko Kisaka, Yasuki Kihara. (2011) Platelet Function Measured Using a Whole Blood Aggregometer Can Predict Bleeding Events. Journal of Atherosclerosis and Thrombosis 18:1, 16-23
CrossRef192
D J Angiolillo, C M Gibson, S Cheng, C Ollier, O Nicolas, L Bergougnan, L Perrin, F P LaCreta, F Hurbin, M Dubar. (2011) Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies. Clinical Pharmacology & Therapeutics 89:1, 65-74
CrossRef193
Jun-Beom Lee, Kyung-A Lee, Kyung-Yul Lee. (2011) Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease. Yonsei Medical Journal 52:5, 734
CrossRef194
Hiroshi YASUDA. (2011) 3. Risk of Upper Gastrointestinal Bleeding during Clopidogrel Therapy with or without a PPI. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 42:6, 369-373
CrossRef195
P. A. Gurbel, U. S. Tantry. (2011) Clopidogrel response variability and the advent of personalised antiplatelet therapy. Thrombosis and Haemostasis 106:2, 265-271
CrossRef196
Mitsushige SUGIMOTO, Takahiro UOTANI, Masafumi NISHINO, Mihoko YAMADE, Shu SAHARA, Takahisa FURUTA. (2011) 2. As a Gastroenterologist; Supportive Situation for Concomitant Treatment with PPI and Anti-Platelet Drug. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 42:6, 361-367
CrossRef197
T. Gremmel, S. Panzer. (2011) Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thrombosis and Haemostasis 106:2, 211-218
CrossRef198
H. Fernando, A. M. Dart, K. Peter, J. A. Shaw. (2011) Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thrombosis and Haemostasis 105:6, 933-944
CrossRef199
Seung-Pyo Lee, Jang-Whan Bae, Kyung Woo Park, Seung-Woon Rha, Jang-Ho Bae, Jung-Won Suh, In-Ho Chae, Myeong-Chan Cho, Hyo-Soo Kim. (2011) Inhibitory Interaction Between Calcium Channel Blocker and Clopidogrel. Circulation Journal 75:11, 2581-2589
CrossRef200
Takahiro Sawada, Toshiro Shinke, Junya Shite, Tomoyuki Honjo, Yoko Haraguchi, Ryo Nishio, Masakazu Shinohara, Ryuji Toh, Tatsuro Ishida, Hiroyuki Kawamori, Amane Kozuki, Takumi Inoue, Hirotoshi Hariki, Ken-ichi Hirata. (2011) Impact of Cytochrome P450 2C19*2 Polymorphism on Intra-Stent Thrombus After Drug-Eluting Stent Implantation in Japanese Patients Receiving Clopidogrel. Circulation Journal 75:1, 99-105
CrossRef201
Alan HB Wu. (2011) Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clinical Proteomics 8:1, 12
CrossRef202
Tetsuya Tanigawa, Toshio Watanabe, Yuji Nadatani, Koji Otani, Hirohisa Machida, Hirotoshi Okazaki, Hirokazu Yamagami, Kenji Watanabe, Kazunari Tominaga, Yasuhiro Fujiwara, Tetsuo Arakawa. (2011) Gastrointestinal Bleeding after Percutaneous Coronary Intervention. Digestion 83:3, 153-160
CrossRef203
Elie Dolgin. (2011) Behind the paper: Stepping up to the antiplatelet. Nature Medicine 17:1, 42-42
CrossRef204
Jonas B. Olesen, Gunnar H. Gislason, Mette G. Charlot, Emil L. Fosbøl, Charlotte Andersson, Peter Weeke, Ole Ahlehoff, Christian Selmer, Christian Torp-Pedersen, Peter R. Hansen. (2011) Calcium-Channel Blockers Do Not Alter the Clinical Efficacy of Clopidogrel After Myocardial Infarction. Journal of the American College of Cardiology 57:4, 409-417
CrossRef205
J.K. Aronson. 2011. Drugs that affect blood coagulation, fibrinolysis, and hemostasis. , 707-739.
CrossRef206
Hirotoshi ECHIZEN. (2011) 1. Historical Perspective on the Pros and Cons of Coadministration of Proton Pump Inhibitors with Thienopyridine Antiplatelet Drugs (Clopidogrel and Prasugrel). Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 42:6, 357-360
CrossRef207
V. E. Valkhoff, G. W. ‘t Jong, E. M. Van Soest, E. J. Kuipers, M. C. J. M. Sturkenboom. (2011) Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Alimentary Pharmacology & Therapeutics 33:1, 77-88
CrossRef208
L. Yukhanyan, M. K. Freynhofer, J. Siller-Matula, K. Schrör, K. Huber. (2011) Genetic variability in response to clopidogrel therapy and its clinical implications. Thrombosis and Haemostasis 105:Suppl. 1, S55-S59
CrossRef209
D. Sibbing, R. A. Byrne, I. Bernlochner, A. Kastrati. (2011) High platelet reactivity and clinical outcome – Fact and fiction. Thrombosis and Haemostasis 106:2, 191-202
CrossRef210
Yamin Liu, Naifeng Liu, Weilan Li, Hua Shao. (2011) Clopidogrel Response Variability and Its Correlation with Early Recurrent Cardiovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention. Pharmacology 87:5-6, 321-330
CrossRef211
P. Fefer, S. Matetzky. (2011) The genetic basis of platelet responsiveness to clopidogrel. Thrombosis and Haemostasis 106:2, 203-210
CrossRef212
Alf-Aage R Pettersen, Harald Arnesen, Trine B Opstad, Ingebjorg Seljeflot. (2011) The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. Thrombosis Journal 9:1, 4
CrossRef213
David Erlinge. 2011. P2Y Receptors in Health and Disease. , 417-439.
CrossRef214
Qiang Fu, Nobuaki Suzuki, Kaoru Takada, Hirosada Yamamoto, Shuichi Ishikawa, Naoyuki Yokoyama, Ken Kozuma, Takaaki Isshiki. (2011) Effect of cilostazol on optimized standard antiplatelet therapy in a patient with a cytochrome P450 2C19 *2/*2 genotype. Cardiovascular Intervention and Therapeutics 26:1, 79-82
CrossRef215
Seok-Jae Hwang, Young-Hoon Jeong, In-Suk Kim, Jin-Sin Koh, Min-Kyung Kang, Yongwhi Park, Choong Hwan Kwak, Jin-Yong Hwang. (2011) The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Thrombosis Research 127:1, 23-28
CrossRef216
B.M. Brainard, K.L. Epstein, D. LoBato, S. Kwon, M.G. Papich, J.N. Moore. (2011) Effects of Clopidogrel and Aspirin on Platelet Aggregation, Thromboxane Production, and Serotonin Secretion in Horses. Journal of Veterinary Internal Medicine 25:1, 116-122
CrossRef217
Hui Chen, Guangwei Yu, Hong Sun, Xiaoying Wu, Huan Wang. (2011) Comparison of Adjunctive Naoxintong versus Clopidogrel in Volunteers with the CYP2C19*2 Gene Mutation Accompanied with Qi Deficiency and Blood Stasis Constitution. Evidence-Based Complementary and Alternative Medicine 2011, 1-10
CrossRef218
Masakatsu NISHIKAWA, Hiroyoshi HIDAKA. (2011) Future prospective of phosphodiesterase-3 inhibitors as antithorombotic drug. Japanese Journal of Thrombosis and Hemostasis 22:6, 363-367
CrossRef219
Shao-di Yan, Mao Chen, Qiao Li, Xiao-jing Liu, Yong Peng, Hua Chai, Yuan-ning Xu, Jia-fu Wei, De-jia Huang. (2011) The Value of Combining CYP2C19*2 Polymorphism with Classic Risk Factors in Prediction of Clinical Prognosis in Acute Coronary Syndrome Patients. Cardiology 119:1, 15-20
CrossRef220
David P. Faxon. (2011) Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef221
G Suarez-Kurtz, J P Genro, M O de Moraes, E B Ojopi, S D J Pena, J A Perini, A Ribeiro-dos-Santos, M A Romano-Silva, I Santana, C J Struchiner. (2010) Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. The Pharmacogenomics Journal
CrossRef222
A. M. Harmsze, J. W. van Werkum, J. M. ten Berg, B. Zwart, H. J. Bouman, N. J. Breet, A. W. J. van 't Hof, H. J. T. Ruven, C. M. Hackeng, O. H. Klungel, A. de Boer, V. H. M. Deneer. (2010) CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. European Heart Journal 31:24, 3046-3053
CrossRef223
K. Huber. (2010) Genetic variability in response to clopidogrel therapy: clinical implications. European Heart Journal 31:24, 2974-2976
CrossRef224
P. W. Radke, H. Schunkert. (2010) Diabetics with acute coronary syndrome: advances, challenges, and uncertainties. European Heart Journal 31:24, 2971-2973
CrossRef225
Neena S. Abraham, Mark A. Hlatky, Elliott M. Antman, Deepak L. Bhatt, David J. Bjorkman, Craig B. Clark, Curt D. Furberg, David A. Johnson, Charles J. Kahi, Loren Laine, Kenneth W. Mahaffey, Eamonn M. Quigley, James Scheiman, Laurence S. Sperling, Gordon F. Tomaselli. (2010) ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology 56:24, 2051-2066
CrossRef226
David M. Greer. (2010) Aspirin and Antiplatelet Agent Resistance. CNS Drugs 24:12, 1027-1040
CrossRef227
Savanna Steele, Craig R Lee. (2010) Research Highlights. Pharmacogenomics 11:12, 1687-1690
CrossRef228
P. Barash, S. Akhtar. (2010) Coronary stents: factors contributing to perioperative major adverse cardiovascular events. British Journal of Anaesthesia 105:Supplement 1, i3-i15
CrossRef229
Amanda J Rhee, Ronald A Kahn. (2010) Laboratory point-of-care monitoring in the operating room. Current Opinion in Anaesthesiology 23:6, 741-748
CrossRef230
Thor Wilhelm Bjelland, Øyvind Hjertner, Pål Klepstad, Kjell Kaisen, Ola Dale, Bjørn Olav Haugen. (2010) Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation 81:12, 1627-1631
CrossRef231
J Woodcock. (2010) Assessing the Clinical Utility of Diagnostics Used in Drug Therapy. Clinical Pharmacology & Therapeutics 88:6, 765-773
CrossRef232
HJ TAN. (2010) Controversy of proton pump inhibitor and clopidogrel interaction: A review. Journal of Digestive Diseases 11:6, 334-342
CrossRef233
AHMED ABDEL-LATIF, DAVID J. MOLITERNO. (2010) Editorial: Protein C and S Deficiency as a Risk Factor for Stent Thrombosis-When a Rare Disorder Can Predispose to Rare Events. Journal of Interventional Cardiology 23:6, 565-568
CrossRef234
L. Lorgis, C. Richard, M. Zeller, A. Gudjoncik, P. Buffet, I. L’Huillier, Y. Cottin. (2010) Les anti-agrégants plaquettaires au cours du syndrome coronarien aigu. Données des grandes études. Annales de Cardiologie et d'Angéiologie 59, S47-S55
CrossRef235
B. Mannheimer, E. Eliasson. (2010) Drug-drug interactions that reduce the formation of pharmacologically active metabolites: a poorly understood problem in clinical practice. Journal of Internal Medicine 268:6, 540-548
CrossRef236
I. S. Mackenzie, M. W. H. Coughtrie, T. M. MacDonald, L. Wei. (2010) Antiplatelet drug interactions. Journal of Internal Medicine 268:6, 516-529
CrossRef237
T. Simon. (2010) Pharmacogénétique des antagonistes des récepteurs plaquettaire P2Y12 de l’ADP. Annales de Cardiologie et d'Angéiologie 59, S42-S46
CrossRef238
Raute Sunder-Plassmann, Christine Mannhalter. (2010) Pharmacogenetics guided anticoagulation. Clinical Chemistry and Laboratory Medicine 48:S1, S119-S127
CrossRef239
Paul M. Brown. (2010) Personalized medicine and comparative effectiveness research in an era of fixed budgets. The EPMA Journal 1:4, 633-640
CrossRef240
Annemarie M. Armani. (2010) Prasugrel. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:4, 199-202
CrossRef241
D K Burns. (2010) Developing Pharmacogenetic Evidence Throughout Clinical Development. Clinical Pharmacology & Therapeutics 88:6, 867-870
CrossRef242
Neena S Abraham, Mark A Hlatky, Elliott M Antman, Deepak L Bhatt, David J Bjorkman, Craig B Clark, Curt D Furberg, David A Johnson, Charles J Kahi, Loren Laine, Kenneth W Mahaffey, Eamonn M Quigley, James Scheiman, Laurence S Sperling, Gordon F Tomaselli. (2010) ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. The American Journal of Gastroenterology 105:12, 2533-2549
CrossRef243
Julio Marchini, David Morrow, Frederic Resnic, Andre Manica, James Kirshenbaum, Christopher Cannon, Kevin Croce. (2010) An Algorithm for Use of Prasugrel (Effient) in Patients Undergoing Cardiac Catheterization and Percutaneous Coronary Intervention. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:4, 192-198
CrossRef244
Bhatt, Deepak L., Cryer, Byron L., Contant, Charles F., Cohen, Marc, Lanas, Angel, Schnitzer, Thomas J., Shook, Thomas L., Lapuerta, Pablo, Goldsmith, Mark A., Laine, Loren, Scirica, Benjamin M., Murphy, Sabina A., Cannon, Christopher P., . (2010) Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal of Medicine 363:20, 1909-1917
Full Text245
, Bob Wilffert, Jesse Swen, Hans Mulder, Daan Touw, Anke-Hilse Maitland-Van der Zee, Vera Deneer. (2010) From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Pharmacy World & Science
CrossRef246
Anne Bellemain-Appaix, David Brieger, Farzin Beygui, Johanne Silvain, Ana Pena, Guillaume Cayla, Olivier Barthélémy, Jean-Philippe Collet, Gilles Montalescot. (2010) New P2Y12 Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention. Journal of the American College of Cardiology 56:19, 1542-1551
CrossRef247
Antonio J. López Farré, Juan Tamargo, Petra J. Mateos-Cáceres, Luís Azcona, Carlos Macaya. (2010) Old and New Molecular Mechanisms Associated with Platelet Resistance to Antithrombotics. Pharmaceutical Research 27:11, 2365-2373
CrossRef248
Karin Müller, Simon Aichele, Mario Herkommer, Boris Bigalke, Konstantinos Stellos, Patrik Htun, Suzanne Fateh-Moghadam, Andreas E. May, Marcus Flather, Meinrad Gawaz, Tobias Geisler. (2010) Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 213:1, 256-262
CrossRef249
(2010) CardioPulse Articles * Focused Update of the ESC Guidelines on device therapy in heart failure * ESC recommendations for individual certification and institutional cardiovascular magnetic resonance accreditation, in Europe * The final, Climbing the academic ladder in cardiology: USA * There are two different career tracks for academic medicine in the USA * Company success: Genzyme * Genzyme's research in cardiovascular disease, putting rare conditions on centre stage * Towards individualized preventive therapy. European Heart Journal 31:21, 2559-2566
CrossRef250
Chadi Dib, Elias B. Hanna, Mazen S. Abu-Fadel. (2010) A New Era for Antiplatelet Therapy in Patients With Acute Coronary Syndrome. The American Journal of the Medical Sciences 340:5, 407-411
CrossRef251
Pei-Wen Hsieh, Yu-Ting Chang, Wen Yin Chuang, Hsin-Chu Shih, Shin-Zan Chiang, Chin-Chung Wu. (2010) The synthesis and biologic evaluation of anti-platelet and cytotoxic β-nitrostyrenes. Bioorganic & Medicinal Chemistry 18:21, 7621-7627
CrossRef252
Denis M McCarthy. (2010) Adverse effects of proton pump inhibitor drugs: clues and conclusions. Current Opinion in Gastroenterology 26:6, 624-631
CrossRef253
Leslie Garson, Bill Bruns. (2010) An innovative software solution for personalized pharmacotherapy. Therapeutic Delivery 1:5, 643-650
CrossRef254
Stephen D. Wiviott, Jessica L. Mega. (2010) Another Step on the Road to Tailored Antiplatelet Therapy
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 56:20, 1637-1638
CrossRef255
A. A. C. M. HEESTERMANS, J. W. VAN WERKUM, B. ZWART, J. A. VAN DER HEYDEN, J. C. KELDER, N. J. BREET, A. W. J. VAN'T HOF, J.-H. E. DAMBRINK, J. J. KOOLEN, B. R. G. BRUEREN, F. ZIJLSTRA, J. M. TEN BERG. (2010) Acute and subacute stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: incidence, predictors and clinical outcome. Journal of Thrombosis and Haemostasis 8:11, 2385-2393
CrossRef256
Laurent Bonello, Sébastien Armero, Omar Ait Mokhtar, Julien Mancini, Philippe Aldebert, Noémie Saut, Nathalie Bonello, Paul Barragan, Stéphane Arques, Marie-Paule Giacomoni, Caroline Bonello-Burignat, Marie-Noelle Bartholomei, Françoise Dignat-George, Laurence Camoin-Jau, Franck Paganelli. (2010) Clopidogrel Loading Dose Adjustment According to Platelet Reactivity Monitoring in Patients Carrying the 2C19*2 Loss of Function Polymorphism. Journal of the American College of Cardiology 56:20, 1630-1636
CrossRef257
Thomas Gremmel, Sabine Steiner, Daniela Seidinger, Renate Koppensteiner, Simon Panzer, Christoph W Kopp. (2010) The Influence of Proton Pump Inhibitors on the Antiplatelet Potency of Clopidogrel Evaluated by 5 Different Platelet Function Tests. Journal of Cardiovascular Pharmacology 56:5, 532-539
CrossRef258
Shashi Amur, Issam Zineh, Darrell R Abernethy, Shiew-Mei Huang, Lawrence J Lesko. (2010) Pharmacogenomics and adverse drug reactions. Personalized Medicine 7:6, 633-642
CrossRef259
Laurent Bonello, Nathalie Palot-Bonello, Sébastien Armero, Laurence Camoin-Jau, Franck Paganelli. (2010) Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2
CrossRef260
Matthew Sibbald, Andrew T. Yan, Wei Huang, Keith A.A. Fox, Joel M. Gore, Ph. Gabriel Steg, Kim A. Eagle, David Brieger, Gilles Montalescot, Shaun G. Goodman. (2010) Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: Insights from the Global Registry of Acute Coronary Events. American Heart Journal 160:5, 855-861
CrossRef261
Paré, Guillaume, Mehta, Shamir R., Yusuf, Salim, Anand, Sonia S., Connolly, Stuart J., Hirsh, Jack, Simonsen, Katy, Bhatt, Deepak L., Fox, Keith A.A., Eikelboom, John W., . (2010) Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment. New England Journal of Medicine 363:18, 1704-1714
Full Text262
Michael A. Gaglia, Steven V. Manoukian, Ron Waksman. (2010) Novel antiplatelet therapy. American Heart Journal 160:4, 595-604
CrossRef263
Colin M. Barker, Sarah S. Murray, Paul S. Teirstein, David E. Kandzari, Eric J. Topol, Matthew J. Price. (2010) Pilot Study of the Antiplatelet Effect of Increased Clopidogrel Maintenance Dosing and Its Relationship to CYP2C19 Genotype in Patients With High On-Treatment Reactivity. JACC: Cardiovascular Interventions 3:10, 1001-1007
CrossRef264
Jessica L Mega, Sandra L Close, Stephen D Wiviott, Lei Shen, Joseph R Walker, Tabassome Simon, Elliott M Antman, Eugene Braunwald, Marc S Sabatine. (2010) Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis. The Lancet 376:9749, 1312-1319
CrossRef265
Patrick Gladding, Laura Panattoni, Mark Webster, Leslie Cho, Stephen Ellis. (2010) Clopidogrel Pharmacogenomics: Next Steps. JACC: Cardiovascular Interventions 3:10, 995-1000
CrossRef266
X. DELAVENNE, N. MALLOUK, M. PIOT, P. MISMETTI, S. LAPORTE. (2010) Is there really a relationship between the plasma concentration of the active metabolite of clopidogrel and the results of platelet function tests?. Journal of Thrombosis and Haemostasis 8:10, 2334-2338
CrossRef267
Łukasz A Małek, Adam Witkowski. (2010) Use of antiplatelet therapies during primary percutaneous coronary intervention for acute myocardial infarction. Interventional Cardiology 2:5, 705-718
CrossRef268
Marco Cattaneo, Gian Marco Podda. (2010) State of the art of new P2Y12 antagonists. Internal and Emergency Medicine 5:5, 385-391
CrossRef269
Rossella Marcucci, Gian Franco Gensini. (2010) High on-clopidogrel platelet reactivity and risk of MACE after PCI with stent implantation. Interventional Cardiology 2:5, 619-621
CrossRef270
Junjie Feng, Jielin Sun, Michael Zhuo Wang, Zheng Zhang, Seong-Tae Kim, Yi Zhu, Jishan Sun, Jianfeng Xu. (2010) Compilation of a comprehensive gene panel for systematic assessment of genes that govern an individual’s drug responses. Pharmacogenomics 11:10, 1403-1425
CrossRef271
David R. Holmes, Dean J. Kereiakes, Scot Garg, Patrick W. Serruys, Gregory J. Dehmer, Stephen G. Ellis, David O. Williams, Takeshi Kimura, David J. Moliterno. (2010) Stent Thrombosis. Journal of the American College of Cardiology 56:17, 1357-1365
CrossRef272
Lars Wallentin, Stefan James, Robert F Storey, Martin Armstrong, Bryan J Barratt, Jay Horrow, Steen Husted, Hugo Katus, P Gabriel Steg, Svati H Shah, Richard C Becker. (2010) Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. The Lancet 376:9749, 1320-1328
CrossRef273
Sergio Leonardi, Pierluigi Tricoci, Richard C. Becker. (2010) Thrombin Receptor Antagonists for the Treatment of Atherothrombosis. Drugs 70:14, 1771-1783
CrossRef274
Robert S. Epstein, J. Russell Teagarden. (2010) Comparative Effectiveness Research and Personalized Medicine. PharmacoEconomics 28:10, 905-913
CrossRef275
Yoshihiro Isomura, Yutaka Yamaji, Miki Ohta, Motoko Seto, Yoshinari Asaoka, Yasuo Tanaka, Takashi Sasaki, Yousuke Nakai, Naoki Sasahira, Hiroyuki Isayama, Minoru Tada, Haruhiko Yoshida, Takao Kawabe, Masao Omata, Kazuhiko Koike. (2010) A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer. Journal of Gastroenterology 45:10, 1045-1052
CrossRef276
Pier Mannuccio Mannucci, Massimo Franchini. (2010) New antiplatelet agents in acute coronary syndromes (ACS): An update. European Journal of Internal Medicine 21:5, 465-466
CrossRef277
Christopher Ombrello, Robert C. Block, Craig N. Morrell. (2010) Our Expanding View of Platelet Functions and Its Clinical Implications. Journal of Cardiovascular Translational Research 3:5, 538-546
CrossRef278
Young-Hoon Jeong, Jung-Hyun Cho, Min-Kyung Kang, Jin-Sin Koh, In-Suk Kim, Yongwhi Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang. (2010) Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction. Thrombosis Research 126:4, e334-e338
CrossRef279
Samuel Chackalamannil. 2010. Antiplatelet Agents. .
CrossRef280
Dominick J. Angiolillo, Jorge F. Saucedo, Roger DeRaad, Andrew L. Frelinger, Paul A. Gurbel, Timothy M. Costigan, Joseph A. Jakubowski, Clement K. Ojeh, Mark B. Effron. (2010) Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology 56:13, 1017-1023
CrossRef281
Fabio Mangiacapra, Emanuele Barbato. (2010) Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical Outcome. High Blood Pressure & Cardiovascular Prevention 17:3, 121-130
CrossRef282
S Rosenborg, M Stenberg, S Otto, J Östervall, M Masquelier, Q-Y Yue, L Bertilsson, E Eliasson. (2010) Clinically Significant CYP2C Inhibition by Noscapine but Not by Glucosamine. Clinical Pharmacology & Therapeutics 88:3, 343-346
CrossRef283
Klaus A. Tiroch, Dirk Sibbing, Werner Koch, Tobias Roosen-Runge, Julinda Mehilli, Albert Schömig, Adnan Kastrati. (2010) Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. American Heart Journal 160:3, 506-512
CrossRef284
Takahisa Furuta, Takayuki Iwaki, Kazuo Umemura. (2010) Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. British Journal of Clinical Pharmacology 70:3, 383-392
CrossRef285
Laurent Bonello, Udaya S. Tantry, Rossella Marcucci, Ruediger Blindt, Dominick J. Angiolillo, Richard Becker, Deepak L. Bhatt, Marco Cattaneo, Jean Philippe Collet, Thomas Cuisset, Christian Gachet, Gilles Montalescot, Lisa K. Jennings, Dean Kereiakes, Dirk Sibbing, Dietmar Trenk, Jochem W. Van Werkum, Franck Paganelli, Matthew J. Price, Ron Waksman, Paul A. Gurbel. (2010) Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. Journal of the American College of Cardiology 56:12, 919-933
CrossRef286
Ingolf Cascorbi. (2010) Safe and effective medicines for all: is personalized medicine the answer?. Expert Review of Clinical Pharmacology 3:5, 627-637
CrossRef287
Jeremy S. Paikin, John W. Eikelboom, John A. Cairns, Jack Hirsh. (2010) New antithrombotic agents—insights from clinical trials. Nature Reviews Cardiology 7:9, 498-509
CrossRef288
Daniel Duerschmied, Christoph Bode, Martin Moser. (2010) Clopidogrel in acute coronary syndrome: implications of recent study findings. Expert Review of Cardiovascular Therapy 8:9, 1215-1229
CrossRef289
John Jason Sutton, Colin M. Barker. (2010) Is There a Role for Platelet Function Testing for Patients on Chronic Dual Antiplatelet Therapy?. Current Cardiovascular Risk Reports 4:5, 327-331
CrossRef290
Anja Zahno, Karin Brecht, Michael Bodmer, Daniel Bur, Dimitrios A Tsakiris, Stephan Krähenbühl. (2010) Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. British Journal of Pharmacology 161:2, 393-404
CrossRef291
Junbo Ge, Junren Zhu, Bum-Kee Hong, Sarana Boonbaichaiyapruck, Yew Seong Goh, Charles Jia-Yin Hou, Philippe Pinton. (2010) Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. Current Medical Research and Opinion 26:9, 2077-2085
CrossRef292
Kensaku Nishihira, Atsushi Yamashita, Tetsunori Ishikawa, Kinta Hatakeyama, Yoshisato Shibata, Yujiro Asada. (2010) Composition of thrombi in late drug-eluting stent thrombosis versus de novo acute myocardial infarction. Thrombosis Research 126:3, 254-257
CrossRef293
David Taylor, Eman Al-Saeed. (2010) Can (and will) governments afford personalized medicine?. Personalized Medicine 7:5, 587-595
CrossRef294
Matthias Orth, Alexander Eduard Rosler. (2010) Thrombozytenhemmende Therapie in der Kardiologie: aktuelle Entwicklungen bei Therapie und Monitoring / Antiplatelet drugs in cardiology: current trends in therapy and monitoring. LaboratoriumsMedizin 34:5, 261-269
CrossRef295
Matthias Orth, Alexander Eduard Rosler. (2010) Antiplatelet drugs in cardiology: current trends in therapy and monitoring 1. LaboratoriumsMedizin 34:5, ---
CrossRef296
Prakash A. Patel, John G.T. Augoustides. (2010) Progress in Platelet Medicine: Focus on Stent Thrombosis and Drug Resistance. Journal of Cardiothoracic and Vascular Anesthesia 24:4, 722-727
CrossRef297
Ingolf Cascorbi. (2010) The promises of personalized medicine. European Journal of Clinical Pharmacology 66:8, 749-754
CrossRef298
Anne Flöck, Astrid Zobel, Gerhard Bauriedel, Izabela Tuleta, Christoph Hammerstingl, Susanne Höfels, Anna Schuhmacher, Wolfgang Maier, Georg Nickenig, Dirk Skowasch. (2010) Antiplatelet effects of antidepressant treatment: A randomized comparison between escitalopram and nortriptyline. Thrombosis Research 126:2, e83-e87
CrossRef299
Rolf P Kreutz, Eric J Stanek, Ronald Aubert, Jianying Yao, Jeffrey A Breall, Zeruesenay Desta, Todd C Skaar, J. Russell Teagarden, Felix W Frueh, Robert S Epstein, David A Flockhart. (2010) Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study. Pharmacotherapy 30:8, 787-796
CrossRef300
Tobias Geisler, Meinrad Gawaz, Steven R. Steinhubl, Deepak L. Bhatt, Robert F. Storey, Marcus Flather. (2010) Current strategies in antiplatelet therapy — Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. Pharmacology & Therapeutics 127:2, 95-107
CrossRef301
Alessio Squassina, Mirko Manchia, Vangelis G Manolopoulos, Mehmet Artac, Christina Lappa-Manakou, Sophia Karkabouna, Konstantinos Mitropoulos, Maria Del Zompo, George P Patrinos. (2010) Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics 11:8, 1149-1167
CrossRef302
H.- S. Kang, B. J. Kwon, J. E. Kim, M. H. Han. (2010) Preinterventional Clopidogrel Response Variability for Coil Embolization of Intracranial Aneurysms: Clinical Implications. American Journal of Neuroradiology 31:7, 1206-1210
CrossRef303
M. J. SORICH, A. VITRY, M. B. WARD, J. D. HOROWITZ, R. A. MCKINNON. (2010) Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis and Haemostasis 8:8, 1678-1684
CrossRef304
D. SIBBING, D. GEBHARD, W. KOCH, S. BRAUN, J. STEGHERR, T. MORATH, N. VON BECKERATH, J. MEHILLI, A. SCHÖMIG, T. SCHUSTER, A. KASTRATI. (2010) Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. Journal of Thrombosis and Haemostasis 8:8, 1685-1693
CrossRef305
Nicolas Danchin, Nadia Aïssaoui. (2010) Pharmacologic Therapy for Non ST-segment Elevation Acute Coronary Syndromes: Focus on Antithrombotic Therapy. Cardiovascular Drugs and Therapy 24:4, 325-330
CrossRef306
Kumaran Kolandaivelu, Deepak L. Bhatt. (2010) Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nature Reviews Cardiology 7:8, 461-467
CrossRef307
S.H. Meves, U. Overbeck, A. Kaiser, C. Krogias, H. Neubauer. (2010) Umstellung von Clopidogrel-Hydrogensulfat auf Clopidogrel-Besilat. Der Nervenarzt 81:8, 992-997
CrossRef308
H. M. JUDGE, S. B. PATIL, R. J. BUCKLAND, J. A. JAKUBOWSKI, R. F. STOREY. (2010) Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel. Journal of Thrombosis and Haemostasis 8:8, 1820-1827
CrossRef309
Ryuichi Ogawa, Hirotoshi Echizen. (2010) Drug-Drug Interaction Profiles of Proton Pump Inhibitors. Clinical Pharmacokinetics 49:8, 509-533
CrossRef310
Martin Moser, Christoph Bode. (2010) Antiplatelet therapy for atherothrombotic disease: How can we improve the outcomes?. Journal of Thrombosis and Thrombolysis 30:2, 240-249
CrossRef311
Andrew Shaw, Thomas VandeVen. (2010) Secrets of the perioptome: new tools for a new concept. Current Opinion in Critical Care 16:4, 365-370
CrossRef312
(2010) Duration of Clopidogrel Therapy with Drug-Eluting Stents. New England Journal of Medicine 363:5, 488-490
Full Text313
Neal S. Kleiman. (2010) PLATO Study of Ticagrelor Versus Clopidogrel in Patients With High-Risk Acute Coronary Syndromes. Current Cardiology Reports 12:4, 283-285
CrossRef314
Miles W Behan, Derek P Chew, Philip E Aylward. (2010) The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Current Opinion in Cardiology 25:4, 321-328
CrossRef315
Horst Neubauer, Andreas Engelhardt, Jan C Krüger, Sebastian Lask, Jan Börgel, Andreas Mügge, Heinz G Endres. (2010) Pantoprazole Does Not Influence the Antiplatelet Effect of Clopidogrel-A Whole Blood Aggregometry Study After Coronary Stenting. Journal of Cardiovascular Pharmacology 56:1, 91-97
CrossRef316
Chee Tang Chin, Matthew T. Roe, Keith A.A. Fox, Dorairaj Prabhakaran, Debra A. Marshall, Helene Petitjean, Yuliya Lokhnygina, Eileen Brown, Paul W. Armstrong, Harvey D. White, E. Magnus Ohman. (2010) Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non–ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. American Heart Journal 160:1, 16-22.e1
CrossRef317
C. Richard Conti. (2010) Antiplatelets and Anticoagulants. Clinical Cardiology 33:7, 388-389
CrossRef318
Jean-Sébastien Hulot, Jean-Philippe Collet, Johanne Silvain, Ana Pena, Anne Bellemain-Appaix, Olivier Barthélémy, Guillaume Cayla, Farzin Beygui, Gilles Montalescot. (2010) Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration. Journal of the American College of Cardiology 56:2, 134-143
CrossRef319
Frederic S. Resnic, Akshay Desai. (2010) Highlights from the 59th Annual Scientific Sessions of the American College of Cardiology, March 13 to 17, 2010, Atlanta, Georgia. The Journal of Thoracic and Cardiovascular Surgery 140:1, 257-259
CrossRef320
Yee W Wong, Roshan Prakash, Derek P Chew. (2010) Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. Current Opinion in Cardiology 25:4, 305-311
CrossRef321
David R. Holmes, Gregory J. Dehmer, Sanjay Kaul, Dana Leifer, Patrick T. O'Gara, C. Michael Stein. (2010) ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”. Journal of the American College of Cardiology 56:4, 321-341
CrossRef322
Young-Hoon Jeong, In-Suk Kim, Yongwhi Park, Min-Kyung Kang, Jin-Sin Koh, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang. (2010) Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day. JACC: Cardiovascular Interventions 3:7, 731-741
CrossRef323
Paul A. Gurbel, Udaya S. Tantry, Alan R. Shuldiner, Dean J. Kereiakes. (2010) Genotyping. Journal of the American College of Cardiology 56:2, 112-116
CrossRef324
Ekta Gupta, Darpan Bansal, John Sotos, Kevin Olden. (2010) Risk of Adverse Clinical Outcomes with Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Percutaneous Coronary Intervention. Digestive Diseases and Sciences 55:7, 1964-1968
CrossRef325
Samir B. Damani, Eric J. Topol. (2010) The Case for Routine Genotyping in Dual-Antiplatelet Therapy. Journal of the American College of Cardiology 56:2, 109-111
CrossRef326
C. S. ZUERN, M. SCHWAB, M. GAWAZ, T. GEISLER. (2010) Platelet pharmacogenomics. Journal of Thrombosis and Haemostasis 8:6, 1147-1158
CrossRef327
Jacob George, Alex Doney, Colin N. Palmer, Chim C. Lang. (2010) Pharmacogenetics Testing: Implications for Cardiovascular Therapeutics with Clopidogrel and Warfarin. Cardiovascular Therapeutics 28:3, 135-138
CrossRef328
Soraya El Ghannudi, Patrick Ohlmann, Nicolas Meyer, Marie-Louise Wiesel, Bogdan Radulescu, Michel Chauvin, Pierre Bareiss, Christian Gachet, Olivier Morel. (2010) Impact of P2Y12 Inhibition by Clopidogrel on Cardiovascular Mortality in Unselected Patients Treated by Percutaneous Coronary Angioplasty. JACC: Cardiovascular Interventions 3:6, 648-656
CrossRef329
Ashequl M Islam, Pranav M Patel. (2010) Preventing Serious Sequelae After an Acute Coronary Syndrome: The Consequences of Thrombosis Versus Bleeding With Antiplatelet Therapy. Journal of Cardiovascular Pharmacology 55:6, 585-594
CrossRef330
Fabio Mangiacapra, Emanuele Barbato. (2010) Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. Biomarkers in Medicine 4:3, 421-434
CrossRef331
Fernando D. Testai, Philip B. Gorelick. (2010) New Approaches to Stroke Prevention in Atrial Fibrillation. Current Treatment Options in Cardiovascular Medicine 12:3, 261-273
CrossRef332
Michael A. Gaglia Jr., Ron Waksman. (2010) Proton Pump Inhibitors and Clopidogrel. Cardiovascular Therapeutics 28:3, 169-176
CrossRef333
Nihar R. Desai, Deepak L. Bhatt. (2010) The State of Periprocedural Antiplatelet Therapy After Recent Trials. JACC: Cardiovascular Interventions 3:6, 571-583
CrossRef334
Willibald Hochholzer, Dietmar Trenk, Martin F. Fromm, Christian M. Valina, Christian Stratz, Hans-Peter Bestehorn, Heinz Joachim Büttner, Franz-Josef Neumann. (2010) Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent Placement. Journal of the American College of Cardiology 55:22, 2427-2434
CrossRef335
Finn Gustafsson, Dan Atar, Bertram Pitt, Faiez Zannad, Marc A. Pfeffer. (2010) Maximizing scientific knowledge from randomized clinical trials. American Heart Journal 159:6, 937-943
CrossRef336
Federico M. Goodsaid, Shashi Amur, Jiri Aubrecht, Michael E. Burczynski, Kevin Carl, Jennifer Catalano, Rosane Charlab, Sandra Close, Catherine Cornu-Artis, Laurent Essioux, Albert J. Fornace, Lois Hinman, Huixiao Hong, Ian Hunt, David Jacobson-Kram, Ansar Jawaid, David Laurie, Lawrence Lesko, Heng-Hong Li, Klaus Lindpaintner, James Mayne, Peter Morrow, Marisa Papaluca-Amati, Timothy W. Robison, John Roth, Ina Schuppe-Koistinen, Leming Shi, Olivia Spleiss, Weida Tong, Sharada L. Truter, Jacky Vonderscher, Agnes Westelinck, Li Zhang, Issam Zineh. (2010) Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nature Reviews Drug Discovery 9:6, 435-445
CrossRef337
L. Testa, R. Bhindi, W. J. Van Gaal, R. A. Latini, S. Pizzocri, S. Lanotte, G. G. L. Biondi Zoccai, M. Valgimigli, M. L. Laudisa, N. Brambilla, A. P. Banning, F. Bedogni. (2010) What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. QJM 103:6, 367-377
CrossRef338
Philip E. Empey. (2010) Genetic predisposition to adverse drug reactions in the intensive care unit. Critical Care Medicine 38, S106-S116
CrossRef339
Heng-Lan Kuo, Jin-Cherng Lien, Ching-Hu Chung, Chien-Hsin Chang, Shyh-Chyi Lo, I-Chun Tsai, Hui-Chin Peng, Sheng-Chu Kuo, Tur-Fu Huang. (2010) NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities. Naunyn-Schmiedeberg's Archives of Pharmacology 381:6, 495-505
CrossRef340
D. Sibbing, N. von Beckerath, T. Morath, J. Stegherr, J. Mehilli, N. Sarafoff, S. Braun, S. Schulz, A. Schomig, A. Kastrati. (2010) Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. European Heart Journal 31:10, 1205-1211
CrossRef341
Nilesh J Samani, Maciej Tomaszewski, Heribert Schunkert. (2010) The personal genome—the future of personalised medicine?. The Lancet 375:9725, 1497-1498
CrossRef342
Richard L Seip, Jorge Duconge, Gualberto Ruaño. (2010) Implementing genotype-guided antithrombotic therapy. Future Cardiology 6:3, 409-424
CrossRef343
Euan A Ashley, Atul J Butte, Matthew T Wheeler, Rong Chen, Teri E Klein, Frederick E Dewey, Joel T Dudley, Kelly E Ormond, Aleksandra Pavlovic, Alexander A Morgan, Dmitry Pushkarev, Norma F Neff, Louanne Hudgins, Li Gong, Laura M Hodges, Dorit S Berlin, Caroline F Thorn, Katrin Sangkuhl, Joan M Hebert, Mark Woon, Hersh Sagreiya, Ryan Whaley, Joshua W Knowles, Michael F Chou, Joseph V Thakuria, Abraham M Rosenbaum, Alexander Wait Zaranek, George M Church, Henry T Greely, Stephen R Quake, Russ B Altman. (2010) Clinical assessment incorporating a personal genome. The Lancet 375:9725, 1525-1535
CrossRef344
Simon R. Dixon, Cindy L. Grines, William W. O'Neill. (2010) The Year in Interventional Cardiology. Journal of the American College of Cardiology 55:20, 2272-2286
CrossRef345
Mukesh Singh, Bipin Thapa, Rohit Arora. (2010) Clopidogrel Pharmacogenetics and Its Clinical Implications. American Journal of Therapeutics 17:3, e66-e73
CrossRef346
Bernhard R Winkelmann, David Herrington. (2010) Pharmacogenomics – 10 years of progress: a cardiovascular perspective. Pharmacogenomics 11:5, 613-616
CrossRef347
Debbie Yee, Joanne Meyer, Gina Caliendo, Veronica Oviedo. (2010) Prasugrel, a New Platelet Inhibitor. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:3, 315-323
CrossRef348
Sergio Coccheri. (2010) Antiplatelet Drugs – Do We Need New Options?. Drugs 70:7, 887-908
CrossRef349
Grzegorz Gajos, Pawel Rostoff, Anetta Undas, Wiesława Piwowarska. (2010) Effects of Polyunsaturated Omega-3 Fatty Acids on Responsiveness to Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology 55:16, 1671-1678
CrossRef350
Subhash Banerjee, Ahmad Zankar, Rick Weideman, Bertis Little, Emmanouil S Brilakis. (2010) Concomitant use of clopidogrel and proton-pump inhibitor: a reality check. Interventional Cardiology 2:2, 121-125
CrossRef351
Pamela R. Kushner. (2010) Role of the primary care provider in the diagnosis and management of heartburn. Current Medical Research and Opinion 26:4, 759-765
CrossRef352
Laurent Bonello, Nathalie Bonello-Palot, Sébastien Armero, Caroline Bonello, Omar Ait Mokhtar, Stéphane Arques, Françoise Dignat-George, Laurence Camoin-Jau, Franck Paganelli. (2010) Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. Thrombosis Research 125:4, e167-e170
CrossRef353
Harold L. Dauerman, Deepak L. Bhatt, Daniel D. Gretler, Patricia A. French, Susan S. Smyth, Richard C. Becker. (2010) Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. American Heart Journal 159:4, 508-517.e1
CrossRef354
Sandrin C Bergheanu, Douwe Pons, Ioannis Karalis, Orçun Özsoy, Jeffrey JW Verschuren, Mark M Ewing, Paul HA Quax, J Wouter Jukema. (2010) Genetic determinants of adverse outcome (restenosis, malapposition and thrombosis) after stent implantation. Interventional Cardiology 2:2, 147-157
CrossRef355
Marta Karaźniewicz-Łada, Franciszek Główka, Grzegorz Oszkinis. (2010) Capillary Zone Electrophoresis method for determination of (+)-S clopidogrel carboxylic acid metabolite in human plasma and urine designed for biopharmaceutic studies. Journal of Chromatography B 878:13-14, 1013-1018
CrossRef356
Jean Mantz, Souhayl Dahmani, Catherine Paugam-Burtz. (2010) Outcomes in perioperative care. Current Opinion in Anaesthesiology 23:2, 201-208
CrossRef357
James M. Gebel. (2010) Heterogeneity of Efficacy and Safety of Antiplatelet Therapy in Cardiovascular and Cerebrovascular Disease. American Journal Cardiovascular Drugs 10:2, 115-124
CrossRef358
H. Darius. (2010) Update: orale Thrombozyteninhibitoren in der Kardiologie. Der Internist 51:4, 533-538
CrossRef359
Evan J. Topol. (2010) Pharmacogenomics and the FDA: The Challenges of Incorporating Research into Practice—Is the FDA Hindering Progress?. Biotechnology Law Report 29:2, 147-163
CrossRef360
Michael A. Gaglia, Rebecca Torguson, Nicholas Hanna, Manuel A. Gonzalez, Sara D. Collins, Asmir I. Syed, Itsik Ben-Dor, Gabriel Maluenda, Cedric Delhaye, Kohei Wakabayashi, Zhenyi Xue, William O. Suddath, Kenneth M. Kent, Lowell F. Satler, Augusto D. Pichard, Ron Waksman. (2010) Relation of Proton Pump Inhibitor Use After Percutaneous Coronary Intervention With Drug-Eluting Stents to Outcomes. The American Journal of Cardiology 105:6, 833-838
CrossRef361
Jaya Prakash Sugunaraj, Chandrasekar Palaniswamy, Dhana Rekha Selvaraj, Sri Krishna Chaitanya Arudra, Rishi Sukhija. (2010) Clopidogrel Resistance. American Journal of Therapeutics 17:2, 210-215
CrossRef362
J.-S. HULOT, G. WUERZNER, C. BACHELOT-LOZA, M. AZIZI, A. BLANCHARD, S. PEYRARD, C. FUNCK-BRENTANO, P. GAUSSEM. (2010) Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects. Journal of Thrombosis and Haemostasis 8:3, 610-613
CrossRef363
Jason Evanchan, Michael R. Donnally, Philip Binkley, Ernest Mazzaferri. (2010) Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor After Stent Placement for Acute Myocardial Infarction. Clinical Cardiology 33:3, 168-171
CrossRef364
H. J. BOUMAN, E. PARLAK, J. W. VAN WERKUM, N. J. BREET, H. TEN CATE, C. M. HACKENG, J. M. TEN BERG, D. TAUBERT. (2010) Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. Journal of Thrombosis and Haemostasis 8:3, 482-488
CrossRef365
Kathryn M Momary, Michael P Dorsch, Eric R Bates. (2010) Genetic Causes of Clopidogrel Nonresponsiveness: Which Ones Really Count?. Pharmacotherapy 30:3, 265-274
CrossRef366
Sonny Dandona, Alexandre F.R. Stewart, Robert Roberts. (2010) Genomics in coronary artery disease: Past, present and future. Canadian Journal of Cardiology 26, 56A-59A
CrossRef367
Kathryn M Momary, Michael P Dorsch. (2010) Factors associated with clopidogrel nonresponsiveness. Future Cardiology 6:2, 195-210
CrossRef368
Richard W Grant, Deborah J Wexler. (2010) Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing. Expert Review of Cardiovascular Therapy 8:3, 339-343
CrossRef369
Shangbin Yang, Lihui Xu, Haifeng M. Wu. (2010) Rapid Multiplexed Genotyping for Hereditary Thrombophilia by SELDI-TOF Mass Spectrometry. Diagnostic Molecular Pathology 19:1, 54-61
CrossRef370
Catherine M. Moerenhout, Marc J. Claeys, Steven Haine, Hielko Miljoen, Johan M. Bosmans, Francine Vertessen, Katrien Kluppels, Marc Van der Planken, Christiaan J. Vrints. (2010) Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: Experience with the point-of-care Platelet Function Assay–100 C/ADP. American Heart Journal 159:3, 434-438
CrossRef371
Rahul Sakhuja, Robert W. Yeh, Deepak L. Bhatt. (2010) Antiplatelet Agents in Acute Coronary Syndromes. Current Problems in Cardiology 35:3, 123-170
CrossRef372
Graeme J Hankey, John W Eikelboom. (2010) Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. The Lancet Neurology 9:3, 273-284
CrossRef373
Tina J Liu, Cynthia A Jackevicius. (2010) Drug Interaction Between Clopidogrel and Proton Pump Inhibitors. Pharmacotherapy 30:3, 275-289
CrossRef374
Carl J. Pepine. (2010) Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. Annals of Medicine 42:1, 19-35
CrossRef375
Alan D. Michelson. (2010) Antiplatelet therapies for the treatment of cardiovascular disease. Nature Reviews Drug Discovery 9:2, 154-169
CrossRef376
Terry K.W. Ma, Yat-Yin Lam, Victoria P. Tan, Thomas J. Kiernan, Bryan P. Yan. (2010) Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacology & Therapeutics 125:2, 249-259
CrossRef377
Carlo Patrono, Bianca Rocca. (2010) The Future of Antiplatelet Therapy in Cardiovascular Disease. Annual Review of Medicine 61:1, 49-61
CrossRef378
Elias B. Hanna, David Luke Glancy, Jorge F. Saucedo. (2010) Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes. Cardiovascular Drugs and Therapy 24:1, 61-70
CrossRef379
Chetan Varma. (2010) Clopidogrel and proton pump inhibitors: Are the goal posts shifting?. Thrombosis Research 125:2, 110-111
CrossRef380
C. Thomas Caskey. (2010) Using Genetic Diagnosis to Determine Individual Therapeutic Utility. Annual Review of Medicine 61:1, 1-15
CrossRef381
Seung-Whan Lee, Seong-Wook Park, Sung-Cheol Yun, Young-Hak Kim, Duk-Woo Park, Won-Jang Kim, Jong-Young Lee, Cheol Whan Lee, Myeong-Ki Hong, Jae-Joong Kim, Seung-Jung Park. (2010) Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). American Heart Journal 159:2, 284-291.e1
CrossRef382
M. Matarin, A. Singleton, J. Hardy, J. Meschia. (2010) The genetics of ischaemic stroke. Journal of Internal Medicine 267:2, 139-155
CrossRef383
Loren Laine, Charles Hennekens. (2010) Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction?. The American Journal of Gastroenterology 105:1, 34-41
CrossRef384
P. A. GURBEL, K. P. BLIDEN, M. J. ANTONINO, G. STEPHENS, D. D. GRETLER, M. M. JUREK, R. E. PAKYZ, A. R. SHULDINER, P. B. CONLEY, U. S. TANTRY. (2010) The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c19*2 genotype: first experience in patients. Journal of Thrombosis and Haemostasis 8:1, 43-53
CrossRef385
Haifeng M Wu, LiHui Xu, Daniel D Sedmak, Clay B Marsh, Mark W Wurster. (2010) Personalized healthcare in clotting disorders. Personalized Medicine 7:1, 65-73
CrossRef386
Victor Ly, Lauren Czosnowski, Lauren K McCluggage, Sarah Spinler. (2010) Interaction between clopidogrel and proton-pump inhibitors. Expert Review of Clinical Pharmacology 3:1, 89-102
CrossRef387
Dániel Aradi, András Vorobcsuk, Zsófia Lenkey, Iván Gábor Horváth, András Komócsi. (2010) Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity. Platelets 21:1, 1-10
CrossRef388
Angel Lanas. (2010) Inhibidores de la bomba de protones y clopidogrel en el paciente cardiovascular: ¿riesgo cardiovascular versus riesgo gastrointestinal?. Gastroenterología y Hepatología 33:1, 1-5
CrossRef389
Jean-Etienne Fabre, Mark E. Gurney. (2010) Limitations of current therapies to prevent thrombosis: a need for novel strategies. Molecular BioSystems 6:2, 305
CrossRef390
Takeo YASU, Ryota IKEE, Yoshiyuki MIYASAKA, Hideo CHUBACHI, Shigeru SAITO. (2010) Efficacy and Safety of Concomitant Use of Rabeprazole during Dual-antiplatelet Therapy with Clopidogrel and Aspirin after Drug-eluting Stent Implantation: A Retrospective Cohort Study. YAKUGAKU ZASSHI 130:12, 1743-1750
CrossRef391
Dominick J. Angiolillo, José Luis Ferreiro. (2010) Inhibición del receptor plaquetario P2Y12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras. Revista Española de Cardiología 63:1, 60-76
CrossRef392
Marc Bonaca, Robert P. Giugliano. (2010) Antithrombotics in Acute Coronary Syndromes: Updates from the Past Year. Current Treatment Options in Cardiovascular Medicine 12:1, 84-99
CrossRef393
Tristan M Sissung, Bevin C English, David Venzon, William D Figg, John F Deeken. (2010) Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 11:1, 89-103
CrossRef394
Shepard D. Weiner, LeRoy E. Rabbani. (2010) Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis 29:1, 8-24
CrossRef395
James AS Muldowney, Cassandra D Benge. (2010) Combination therapy with clopidogrel and proton-pump inhibitors. The Lancet 375:9708, 27-28
CrossRef396
Dennis J. Cada, Terri L. Levien, Danial E. Baker. (2010) Formulary Drug Reviews - Prasugrel. Hospital Pharmacy 45:1, 54-66
CrossRef397
L. Testa, G. G. L. Biondi Zoccai, M. Valgimigli, R. A. Latini, S. Pizzocri, S. Lanotte, M. L. Laudisa, N. Brambilla, M. R. Ward, G. A. Figtree, F. Bedogni, R. Bhindi. (2010) Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents. Advances in Hematology 2010, 1-7
CrossRef398
Ankie Harmsze, Jochem W. van Werkum, Heleen J. Bouman, Henk J. Ruven, Nicolien J. Breet, Jurrien M. Ten Berg, Christian M. Hackeng, Mathieu M. Tjoeng, Olaf H. Klungel, Anthonius de Boer, Vera H. Deneer. (2010) Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenetics and Genomics 20:1, 18-25
CrossRef399
Huang-Joe Wang, Wan-Yu Lo, Te-Ling Lu, Haimei Huang. (2010) (−)-Epigallocatechin-3-gallate decreases thrombin/paclitaxel-induced endothelial tissue factor expression via the inhibition of c-Jun terminal NH2 kinase phosphorylation. Biochemical and Biophysical Research Communications 391:1, 716-721
CrossRef400
T. Geisler, C. Zurn, R. Simonenko, M. Rapin, H. Kraibooj, A. Kilias, B. Bigalke, K. Stellos, M. Schwab, A. E. May, C. Herdeg, M. Gawaz. (2010) Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. European Heart Journal 31:1, 59-66
CrossRef401
Noritaka ARIYOSHI, Yukako IGA, Koji HIRATA, Yasunori SATO, Go MIURA, Itsuko ISHII, Seiji NAGAMORI, Mitsukazu KITADA. (2010) Enhanced Susceptibility of HLA-mediated Ticlopidine-induced Idiosyncratic Hepatotoxicity by CYP2B6 Polymorphism in Japanese. Drug Metabolism and Pharmacokinetics 25:3, 298-306
CrossRef402
Jung-Hyun Cho, Young-Hoon Jeong, Yeon-Jeong Ahn, Min-Kyung Kang, Jin-Sin Koh, In-Suk Kim, Yongwhi Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang. (2010) The Impact of Smoking on Post-Clopidogrel Platelet Reactivity in Patients With Acute Myocardial Infarction. Korean Circulation Journal 40:3, 119
CrossRef403
Álvaro Merino, Andrés Grau, Ignacio Segura. (2010) Novedades en el tratamiento antitrombótico en intervencionismo coronario. Revista Española de Cardiología Suplementos 10:4, 34D-41D
CrossRef404
Kazuo Umemura. (2010) Clopidogrel resistance. Nosotchu 32:6, 740-745
CrossRef405
Bastiaan Zwart, Jochem W. Werkum, Antonius A. C. M. Heestermans, Jurriën M. Berg. (2010) Coronary Stent Thrombosis in the Current Era: Challenges and Opportunities for Treatment. Current Treatment Options in Cardiovascular Medicine 12:1, 46-57
CrossRef406
Jane P. F. BAI. (2010) Ongoing Challenges in Drug Interaction Safety: from Exposure to Pharmacogenomics. Drug Metabolism and Pharmacokinetics 25:1, 62-71
CrossRef407
Alfredo Bardají, José A. Barrabés, Juan Sanchis, Pedro L. Sánchez. (2010) Actualización en cardiopatía isquémica. Revista Española de Cardiología 63, 49-60
CrossRef408
Min-Kyung Kang, Young-Hoon Jeong, Seong-Eun Yoon, Jin-Sin Koh, In-Suk Kim, Yongwhi Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang. (2010) Pre-Procedural Platelet Reactivity After Clopidogrel Loading in Korean Patients Undergoing Scheduled Percutaneous Coronary Intervention. Journal of Atherosclerosis and Thrombosis 17:11, 1122-1131
CrossRef409
Harrington, Robert A., Stone, Gregg W., McNulty, Steven, White, Harvey D., Lincoff, A. Michael, Gibson, C. Michael, Pollack, Charles V. Jr., Montalescot, Gilles, Mahaffey, Kenneth W., Kleiman, Neal S., Goodman, Shaun G., Amine, Maged, Angiolillo, Dominick J., Becker, Richard C., Chew, Derek P., French, William J., Leisch, Franz, Parikh, Keyur H., Skerjanec, Simona, Bhatt, Deepak L., . (2009) Platelet Inhibition with Cangrelor in Patients Undergoing PCI. New England Journal of Medicine 361:24, 2318-2329
Full Text410
Richard C Becker, James Scheiman, Harold L Dauerman, Frederick Spencer, Sunil Rao, Marc Sabatine, David A Johnson, Frances Chan, Neena S Abraham, Eamonn M M Quigley. (2009) Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. The American Journal of Gastroenterology 104:12, 2903-2917
CrossRef411
Salman M. Azam, Joseph Jozic. (2009) Variable platelet responsiveness to aspirin and clopidogrel: role of platelet function and genetic polymorphism testing. Translational Research 154:6, 309-313
CrossRef412
Paul de Koning, James Keirns. (2009) Clinical pharmacology, biomarkers and personalized medicine: education please. Biomarkers in Medicine 3:6, 685-700
CrossRef413
Sophie Sheng-Wen Wang, Shang-Shyue Tsai, Po-Chao Hsu, Chun-Yuh Yang, Deng-Chyang Wu. (2009) Concomitant Use of Clopidogrel and Proton Pump Inhibitors or Cimetidine After Acute Myocardial Infarction Would Increase the Risk of Re-Infarction. The American Journal of Gastroenterology 104:12, 3116-3117
CrossRef414
Patricia A. Howard, James L. Vacek. (2009) Potential Interaction between Clopidogrel and Proton Pump Inhibitors. American Journal Cardiovascular Drugs 9:6, 353-359
CrossRef415
Frederick G. Kushner, Mary Hand, Sidney C. Smith, Spencer B. King, Jeffrey L. Anderson, Elliott M. Antman, Steven R. Bailey, Eric R. Bates, James C. Blankenship, Donald E. Casey, Lee A. Green, Judith S. Hochman, Alice K. Jacobs, Harlan M. Krumholz, Douglass A. Morrison, Joseph P. Ornato, David L. Pearle, Eric D. Peterson, Michael A. Sloan, Patrick L. Whitlow, David O. Williams. (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Journal of the American College of Cardiology 54:23, 2205-2241
CrossRef416
Irina Piatkov, Trudi Jones, Colin Rochester. (2009) Cytochrome P450 loss-of-function polymorphism genotyping on the Agilent Bioanalyzer and clinical application. Pharmacogenomics 10:12, 1987-1994
CrossRef417
Jian-Jun Zou, Hong-Wei Fan, Da-Qing Guo, Ying-Bin Li, Song Lin, Yu-Bing Zhu, Cui-Xia Yu, Jie Zhou, Jiang-Hui Liu, Yun-Fang Hu. (2009) Simultaneous Determination of Clopidogrel and Its Carboxylic Acid Metabolite (SR26334) in Human Plasma by LC–ESI–MS–MS: Application to the Therapeutic Drug Monitoring of Clopidogrel. Chromatographia 70:11-12, 1581-1586
CrossRef418
Laurent Bonello, Gilles Lemesle, Axel De Labriolle, Paul Barragan, Laurence Camoin-Jau, Franck Paganelli. (2009) Personalized antiplatelet therapy for coronary artery disease patients: is this the future?. Expert Review of Cardiovascular Therapy 7:12, 1525-1532
CrossRef419
Frederick G. Kushner, Mary Hand, Sidney C. Smith, Spencer B. King, Jeffrey L. Anderson, Elliott M. Antman, Steven R. Bailey, Eric R. Bates, James C. Blankenship, Donald E. Casey, Lee A. Green, Alice K. Jacobs, Judith S. Hochman, Harlan M. Krumholz, Douglass A. Morrison, Joseph P. Ornato, David L. Pearle, Eric D. Peterson, Michael A. Sloan, Patrick L. Whitlow, David O. Williams. (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Catheterization and Cardiovascular Interventions 74:7, E25-E68
CrossRef420
Massimo Franchini, Pier Mannuccio Mannucci. (2009) New antiplatelet agents: Why they are needed. European Journal of Internal Medicine 20:8, 733-738
CrossRef421
Richard C. Becker, James Scheiman, Harold L. Dauerman, Frederick Spencer, Sunil Rao, Marc Sabatine, David A. Johnson, Frances Chan, Neena S. Abraham, Eamonn M.M. Quigley. (2009) Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. Journal of the American College of Cardiology 54:24, 2261-2276
CrossRef422
Marc Cohen. (2009) Oral Antiplatelet Therapy for Acute and Chronic Management of NSTE ACS: Residual Ischemic Risk and Opportunities for Improvement. Cardiovascular Drugs and Therapy 23:6, 489-499
CrossRef423
G. Montalescot, J.-S. Hulot, J.-P. Collet. (2009) Stent thrombosis: who's guilty?. European Heart Journal 30:22, 2685-2688
CrossRef424
Michael J Wagner. (2009) Pharmacogenetics and personal genomes. Personalized Medicine 6:6, 643-652
CrossRef425
Willem Dewilde, Jurriën Ten Berg. (2009) Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST). American Heart Journal 158:5, 713-718
CrossRef426
Daniel R. Guerra, James E. Tcheng. (2009) Prasugrel: Clinical development and therapeutic application. Advances in Therapy 26:11, 999-1011
CrossRef427
Patrick Gladding, Harvey White, Jamie Voss, John Ormiston, Jim Stewart, Peter Ruygrok, Badi Bvaldivia, Ruth Baak, Catherine White, Mark Webster. (2009) Pharmacogenetic Testing for Clopidogrel Using the Rapid INFINITI Analyzer. JACC: Cardiovascular Interventions 2:11, 1095-1101
CrossRef428
Richard C. Becker. (2009) Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists. Journal of Thrombosis and Thrombolysis 28:4, 513-514
CrossRef429
Aamir Badruddin, Philip B. Gorelick. (2009) Antiplatelet therapy for prevention of recurrent stroke. Current Treatment Options in Neurology 11:6, 452-459
CrossRef430
Kyle J Ellis, George A Stouffer, Howard L McLeod, Craig R Lee. (2009) Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 10:11, 1799-1817
CrossRef431
Paul A. Gurbel, Udaya S. Tantry, Alan R. Shuldiner. (2009) The Worry About Clopidogrel “Nonresponsiveness”. JACC: Cardiovascular Interventions 2:11, 1102-1104
CrossRef432
Marie Lordkipanidzé, Jean G. Diodati, Erick Schampaert, Donald A. Palisaitis, Chantal Pharand. (2009) Prevalence of Unresponsiveness to Aspirin and/or Clopidogrel in Patients With Stable Coronary Heart Disease. The American Journal of Cardiology 104:9, 1189-1193
CrossRef433
Robert P. Giugliano, Eugene Braunwald. (2009) The Year in Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology 54:16, 1544-1555
CrossRef434
José Luis Ferreiro, Masafumi Ueno, Dominick J Angiolillo. (2009) Cangrelor: a review on its mechanism of action and clinical development. Expert Review of Cardiovascular Therapy 7:10, 1195-1201
CrossRef435
B. ALEIL, C. LÃON, J.-P. CAZENAVE, C. GACHET. (2009) CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring. Journal of Thrombosis and Haemostasis 7:10, 1747-1749
CrossRef436
Naveen L. Pereira, Richard M. Weinshilboum. (2009) Cardiovascular pharmacogenomics and individualized drug therapy. Nature Reviews Cardiology 6:10, 632-638
CrossRef437
Daniel I. Simon, Sahil A. Parikh. (2009) Hunting for the “Sweet Spot” in P2Y12 Receptor Blockade
CrossRef438
C. Jámbor, M. Spannagl, B. Zwissler. (2009) Perioperatives Management von Patienten mit Koronarstents bei nichtherzchirurgischen Eingriffen. Der Anaesthesist 58:10, 971-985
CrossRef439
Schömig, Albert, . (2009) Ticagrelor — Is There Need for a New Player in the Antiplatelet-Therapy Field?. New England Journal of Medicine 361:11, 1108-1111
Full Text440
José Biller. (2009) Antiplatelet therapy in ischemic stroke: Variability in clinical trials and its impact on choosing the appropriate therapy. Journal of the Neurological Sciences 284:1-2, 1-9
CrossRef441
Alan D Michelson. (2009) New P2Y12 antagonists. Current Opinion in Hematology 16:5, 371-377
CrossRef442
Peter P. Toth, Annemarie Armani. (2009) Thienopyridine therapy and risk for cardiovascular events in secondary prevention. Current Atherosclerosis Reports 11:5, 364-370
CrossRef443
Ahmed Abdel-Latif, David J. Moliterno. (2009) Prasugrel versus clopidogrel in primary PCI: Considerations of the TRITON-TIMI 38 substudy. Current Cardiology Reports 11:5, 323-324
CrossRef444
David S. Small, Rebecca E. Wrishko, C. Steven Ernest, Lan Ni, Kenneth J. Winters, Nagy A. Farid, Ying G. Li, Daniel E. Salazar, Christopher D. Payne. (2009) Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing. Drugs & Aging 26:9, 781-790
CrossRef445
Thomas Cuisset, Corinne Frere, Jacques Quilici, Raphael Poyet, Bénédicte Gaborit, Laurent Bali, Olivier Brissy, Pierre-Emmanuel Morange, Marie-Christine Alessi, Jean-Louis Bonnet. (2009) Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose. Journal of the American College of Cardiology 54:13, 1149-1153
CrossRef446
Elizabeth M. Van Cott. (2009) Point-of-Care Testing in Coagulation. Clinics in Laboratory Medicine 29:3, 543-553
CrossRef447
Marc P. Bonaca, Philippe Gabriel Steg, Laurent J. Feldman, John F. Canales, James J. Ferguson, Lars Wallentin, Robert M. Califf, Robert A. Harrington, Robert P. Giugliano. (2009) Antithrombotics in Acute Coronary Syndromes. Journal of the American College of Cardiology 54:11, 969-984
CrossRef448
Francisco Marín, Rocío González-Conejero, Piera Capranzano, Theodore A. Bass, Vanessa Roldán, Dominick J. Angiolillo. (2009) Pharmacogenetics in Cardiovascular Antithrombotic Therapy. Journal of the American College of Cardiology 54:12, 1041-1057
CrossRef449
Michelle L O'Donoghue, Eugene Braunwald, Elliott M Antman, Sabina A Murphy, Eric R Bates, Yoseph Rozenman, Alan D Michelson, Raymond W Hautvast, Peter N Ver Lee, Sandra L Close, Lei Shen, Jessica L Mega, Marc S Sabatine, Stephen D Wiviott. (2009) Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. The Lancet 374:9694, 989-997
CrossRef450
Stephen D Turner, Dana C Crawford, Marylyn D Ritchie. (2009) Methods for optimizing statistical analyses in pharmacogenomics research. Expert Review of Clinical Pharmacology 2:5, 559-570
CrossRef451
Erika Check Hayden. (2009) Cardiovascular disease gets personal. Nature 460:7258, 940-941
CrossRef452
C. Verstuyft, T. Simon, R. B. Kim. (2009) Personalized medicine and antiplatelet therapy: ready for prime time?. European Heart Journal 30:16, 1943-1963
CrossRef453
L. Wallentin. (2009) P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. European Heart Journal 30:16, 1964-1977
CrossRef454
Michelle O'Donoghue, Elliott M. Antman, Eugene Braunwald, Sabina A. Murphy, P. Gabriel Steg, Ariel Finkelstein, William F. Penny, Viliam Fridrich, Carolyn H. McCabe, Marc S. Sabatine, Stephen D. Wiviott. (2009) The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention. Journal of the American College of Cardiology 54:8, 678-685
CrossRef455
Sean T. Duggan, Gillian M. Keating. (2009) Prasugrel. Drugs 69:12, 1707-1726
CrossRef456
C. FRÉRE, T. CUISSET, B. GABORIT, M.-C. ALESSI, J.-S. HULOT. (2009) The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. Journal of Thrombosis and Haemostasis 7:8, 1409-1411
CrossRef457
C. Varenhorst, S. James, D. Erlinge, J. T. Brandt, O. O. Braun, M. Man, A. Siegbahn, J. Walker, L. Wallentin, K. J. Winters, S. L. Close. (2009) Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. European Heart Journal 30:14, 1744-1752
CrossRef458
F. Van de Werf. (2009) New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?. European Heart Journal 30:14, 1695-1702
CrossRef459
Itsik Ben-Dor, Neal S. Kleiman, Eli Lev. (2009) Assessment, Mechanisms, and Clinical Implication of Variability in Platelet Response to Aspirin and Clopidogrel Therapy. The American Journal of Cardiology 104:2, 227-233
CrossRef460
Sonny Dandona, Robert Roberts. (2009) Genomic view of factors leading to plaque instability. Current Cardiology Reports 11:4, 282-287
CrossRef461
Somjot S. Brar, Gregg W. Stone. (2009) Advances in percutaneous coronary intervention. Current Cardiology Reports 11:4, 245-251
CrossRef462
Harvey D White. (2009) Strategies to minimize bleeding complications of percutaneous coronary intervention. Current Opinion in Cardiology 24:4, 273-278
CrossRef463
C. PATRONO, B. ROCCA. (2009) Aspirin, 110 years later. Journal of Thrombosis and Haemostasis 7, 258-261
CrossRef464
M.-M. Samama, I. Elalamy. (2009) Étude de la variabilité de réponse à l’aspirine et au clopidogrel : résistance clinique et/ou biologique ?. Annales Pharmaceutiques Françaises 67:4, 265-271
CrossRef465
Betti Giusti, Anna Maria Gori, Rossella Marcucci, Rosanna Abbate. (2009) Research Highlights: CYP2C19 genetic variants and clopidogrel responsiveness in acute coronary syndrome: are we ready for individualized therapy?. Pharmacogenomics 10:7, 1131-1133
CrossRef466
Ilse Zündorf, Theo Dingermann. (2009) Clopidogrel und die Pharmakokinetik. Ein aktuelles Problem für Regulatoren. Pharmazie in unserer Zeit 38:4, 360-367
CrossRef467
Susanne, Theo, Nina, Wolfgang, Manfred, Martin, Dietmar, Petra. (2009) Klinisch relevante Interaktion zwischen Clopidogrel und Protonenpumpen-Inhibitoren. Pharmazie in unserer Zeit 38:4, 370-371
CrossRef468
Susanne Alban. (2009) Prasugrel - ein neuer ADP-Rezeptor-Antagonist. Prodrug -Aktivierung als entscheidender Unterschied. Pharmazie in unserer Zeit 38:4, 320-328
CrossRef469
David R. Holmes, Dean J. Kereiakes, Neal S. Kleiman, David J. Moliterno, Giuseppe Patti, Cindy L. Grines. (2009) Combining Antiplatelet and Anticoagulant Therapies. Journal of the American College of Cardiology 54:2, 95-109
CrossRef470
Kurt Huber, Uma Yasothan, Bashar Hamad, Peter Kirkpatrick. (2009) Prasugrel. Nature Reviews Drug Discovery 8:6, 449-450
CrossRef471
José Luis Ferreiro, Dominick J. Angiolillo. (2009) Antiplatelet therapy: Clopidogrel plus PPIs—a dangerous combination?. Nature Reviews Cardiology 6:6, 392-394
CrossRef472
Laurent Becquemont. (2009) Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 10:6, 961-969
CrossRef473
(2009) Cytochrome P-450 Polymorphisms and Response to Clopidogrel. New England Journal of Medicine 360:21, 2249-2251
Full Text474
I.-S. KIM, B.-R. CHOI, Y.-H. JEONG, C. H. KWAK, S. KIM. (2009) The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. Journal of Thrombosis and Haemostasis 7:5, 897-899
CrossRef475
Antwon Robinson, Kanak Das, Santosh KG Koshy, Pranab Das. (2009) Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention. Future Cardiology 5:3, 237-246
CrossRef476
Jean-Sébastien Hulot, Valentin Fuster. (2009) Antiplatelet therapy: Personalized medicine for clopidogrel resistance?. Nature Reviews Cardiology 6:5, 334-336
CrossRef477
Alan HB Wu, Nikolina Babic, Kiang-Teck J Yeo. (2009) Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian. Personalized Medicine 6:3, 315-327
CrossRef478
Shiny Mathewkutty, Darren K McGuire. (2009) Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment. Expert Review of Cardiovascular Therapy 7:5, 541-549
CrossRef479
Colin M. Barker, H. Vernon Anderson. (2009) Acute Coronary Syndromes. Journal of the American College of Cardiology 53:21, 1973-1974
CrossRef480
Jack Ansell. (2009) Personalizing Health Care—Is This the Right Time for Warfarin?. Journal of General Internal Medicine 24:5, 690-691
CrossRef481
Erik L Grove, Steen D Kristensen. (2009) Update on oral antiplatelet therapy: principles, problems and promises. Future Cardiology 5:3, 247-258
CrossRef482
Diana A. Gorog, Joseph M. Sweeny, Valentin Fuster. (2009) Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs—fact or artifact?. Nature Reviews Cardiology
CrossRef483
Piera Capranzano, Jose Luis Ferreiro, Dominick J Angiolillo. (2009) Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy 7:4, 361-369
CrossRef484
Carlo Patrono. (2009) Antiplatelet therapy: The P2Y12 receptor: no active metabolite, no party. Nature Reviews Cardiology 6:4, 271-272
CrossRef485
Joseph M. Sweeny, Diana A. Gorog, Valentin Fuster. (2009) Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nature Reviews Cardiology 6:4, 273-282
CrossRef486
Nihar R. Desai, Jessica L. Mega, Songtao Jiang, Christopher P. Cannon, Marc S. Sabatine. (2009) Interaction Between Cigarette Smoking and Clinical Benefit of Clopidogrel. Journal of the American College of Cardiology 53:15, 1273-1278
CrossRef487
Arthur M. Feldman. (2009) Multinational Trials: Lost in Translation?. Clinical and Translational Science 2:2, 91-91
CrossRef488
Woodcock, Janet, Lesko, Lawrence J., . (2009) Pharmacogenetics — Tailoring Treatment for the Outliers. New England Journal of Medicine 360:8, 811-813
Full Text489
Freedman, Jane E., Hylek, Elaine M., . (2009) Clopidogrel, Genetics, and Drug Responsiveness. New England Journal of Medicine 360:4, 411-413
Full Text490
Hiroshi Yasuda, Masaya Yamada, Susumu Sawada, Yutaka Endo, Kazuaki Inoue, Fuyuki Asano, Youichi Takeyama, Makoto Yoshiba. (2009) Upper Gastrointestinal Bleeding in Patients Receiving Dual Antiplatelet Therapy after Coronary Stenting. Internal Medicine 48:19, 1725-1730
CrossRef491
C. G. Schuhmann, H. Y. Sohn, J. Nagel, M. Spannagl, V. Klauss, F. Krötz. (2009) Clinical management of clopidogrel inefficiency by point of care platelet function testing and individual adjustment of anti-platelet therapy – initial experiences. Platelets 20:7, 498-504
CrossRef492
D. Varon, G. Spectre. (2009) Antiplatelet agents. Hematology 2009:1, 267-272
CrossRef493
Toshikazu Jinnai, Hisanori Horiuchi, Takeru Makiyama, Junichi Tazaki, Tomohisa Tada, Masaharu Akao, Koh Ono, Kozo Hoshino, Yumiko Naruse, Kanako Takahashi, Haruyo Watanabe, Toru Kita, Takeshi Kimura. (2009) Impact of CYP2C19 Polymorphisms on the Antiplatelet Effect of Clopidogrel in an Actual Clinical Setting in Japan. Circulation Journal 73:8, 1498-1503
CrossRef494
Kazuo UMEMURA. (2009) 2. Genetic Polymorphism of CYP2C19 Affects Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Subjects. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 40:6, 261-265
CrossRef495
Toshikazu JINNAI, Hisanori HORIUCHI. (2009) Variability of the antiplatelet effect of clopidogrel in Japanese. Japanese Journal of Thrombosis and Hemostasis 20:6, 589-593
CrossRef496
Yasuhiro NISHIKAWA. (2009) 4. Clinical Perspectives of New Antiplatelet Drugs. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 40:6, 273-278
CrossRef
- Letters
